<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">77742</article-id><article-id pub-id-type="doi">10.7554/eLife.77742</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title><italic>Mir155</italic> regulates osteogenesis and bone mass phenotype via targeting <italic>S1pr1</italic> gene</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-270576"><name><surname>Zheng</surname><given-names>Zhichao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-270577"><name><surname>Wu</surname><given-names>Lihong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4561-9400</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-270578"><name><surname>Li</surname><given-names>Zhicong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-270579"><name><surname>Tang</surname><given-names>Ruoshu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-270580"><name><surname>Li</surname><given-names>Hongtao</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-270581"><name><surname>Huang</surname><given-names>Yinyin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300652"><name><surname>Wang</surname><given-names>Tianqi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300653"><name><surname>Xu</surname><given-names>Shaofen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300654"><name><surname>Cheng</surname><given-names>Haoyu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-270582"><name><surname>Ye</surname><given-names>Zhitong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232802"><name><surname>Xiao</surname><given-names>Dong</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300655"><name><surname>Lin</surname><given-names>Xiaolin</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-231511"><name><surname>Wu</surname><given-names>Gang</given-names></name><email>g.wu@acta.nl</email><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-149802"><name><surname>Jaspers</surname><given-names>Richard T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6951-0952</contrib-id><email>r.t.jaspers@vu.nl</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-269567"><name><surname>Pathak</surname><given-names>Janak L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2576-443X</contrib-id><email>j.pathak@gzhmu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00zat6v61</institution-id><institution>Affiliated Stomatology Hospital of Guangzhou Medical University, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/008xxew50</institution-id><institution>Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00z0j0d77</institution-id><institution>State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01vjw4z39</institution-id><institution>Guangdong Provincial Key Laboratory of Cancer Immunotherapy Research and Guangzhou Key Laboratory of Tumour Immunology Research, Cancer Research Institute, School of Basic Medical Science, Southern Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01vjw4z39</institution-id><institution>Institute of Comparative Medicine &amp; Laboratory Animal Center, Southern Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/008xxew50</institution-id><institution>Department of Oral and Maxillofacial Surgery/Pathology, Amsterdam UMC and Academic Center for Dentistry Amsterdam (ACTA), Amsterdam Movement Science, Vrije Universiteit Amsterdam</institution></institution-wrap><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/008xxew50</institution-id><institution>Department of Oral Cell Biology, Academic Center for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam</institution></institution-wrap><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Trivedi</surname><given-names>Ritu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021wm7p51</institution-id><institution>CSIR-Central Drug Research Institute</institution></institution-wrap><country>India</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>04</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e77742</elocation-id><history><date date-type="received" iso-8601-date="2022-02-09"><day>09</day><month>02</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-03"><day>03</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-02-19"><day>19</day><month>02</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.02.18.480982"/></event></pub-history><permissions><copyright-statement>© 2023, Zheng, Wu, Li et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Zheng, Wu, Li et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-77742-v2.pdf"/><abstract><p>MicroRNA-155 (miR155) is overexpressed in various inflammatory diseases and cancer, in which bone resorption and osteolysis are frequently observed. However, the role of miR155 on osteogenesis and bone mass phenotype is still unknown. Here, we report a low bone mass phenotype in the long bone of <italic>Mir155</italic>-Tg mice compared with wild-type mice. In contrast, <italic>Mir155</italic>-KO mice showed a high bone mass phenotype and protective effect against inflammation-induced bone loss. <italic>Mir155</italic>-KO mice showed robust bone regeneration in the ectopic and orthotopic model, but <italic>Mir155</italic>-Tg mice showed compromised bone regeneration compared with the wild-type mice. Similarly, the osteogenic differentiation potential of bone marrow stromal stem cells (BMSCs) from <italic>Mir155</italic>-KO mice was robust and <italic>Mir155</italic>-Tg was compromised compared with that of wild-type mice. Moreover, <italic>Mir155</italic> knockdown in BMSCs from wild-type mice showed higher osteogenic differentiation potential, supporting the results from <italic>Mir155</italic>-KO mice. TargetScan analysis predicted sphingosine 1-phosphate receptor-1 (<italic>S1pr1</italic>) as a target gene of <italic>Mir155</italic>, which was further confirmed by luciferase assay and <italic>Mir155</italic> knockdown. <italic>S1pr1</italic> overexpression in BMSCs robustly promoted osteogenic differentiation without affecting cell viability and proliferation. Furthermore, osteoclastogenic differentiation of <italic>Mir155</italic>-Tg bone marrow-derived macrophages was inhibited compared with that of wild-type mice. Thus, <italic>Mir155</italic> showed a catabolic effect on osteogenesis and bone mass phenotype via interaction with the <italic>S1pr1</italic> gene, suggesting inhibition of <italic>Mir155</italic> as a potential strategy for bone regeneration and bone defect healing.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>miR155</kwd><kwd>bone mass</kwd><kwd>osteogenesis</kwd><kwd>S1PR1</kwd><kwd>cell viability</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>The Science and Techonolgoy program of Guangzhou</institution></institution-wrap></funding-source><award-id>202201010073</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Lihong</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>The Science and Technology program of Guangzhou</institution></institution-wrap></funding-source><award-id>202201020116</award-id><principal-award-recipient><name><surname>Zheng</surname><given-names>Zhichao</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>The National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>U22A20159</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Lihong</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>The National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82150410451</award-id><principal-award-recipient><name><surname>Pathak</surname><given-names>Janak L</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>The General Guiding Project of Guangzhou</institution></institution-wrap></funding-source><award-id>20201A011105</award-id><principal-award-recipient><name><surname>Zheng</surname><given-names>Zhichao</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>The Medical Scientific Research Foundation of Guangdong Province</institution></institution-wrap></funding-source><award-id>B2020027</award-id><principal-award-recipient><name><surname>Zheng</surname><given-names>Zhichao</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>The Undergraduate Science and Technology Innovation Project of Guangzhou Medical University</institution></institution-wrap></funding-source><award-id>2020A049</award-id><principal-award-recipient><name><surname>Tang</surname><given-names>Ruoshu</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>The High-level University Construction Founding of Guangzhou Medical University</institution></institution-wrap></funding-source><award-id>06-410-2106035 and 02-412-B205002-1003017</award-id><principal-award-recipient><name><surname>Pathak</surname><given-names>Janak L</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value><italic>Mir155</italic> showed a catabolic effect on osteogenesis and bone mass phenotype via interaction with the <italic>S1pr1</italic> gene, suggesting inhibition of <italic>Mir155</italic> as a potential approach to bone regeneration and bone defect healing.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>MicroRNAs (miRNAs) are a class of endogenous non-coding RNAs with 18–22 nucleotides length that bind to the 3′-untranslated region of the target gene and regulate the target gene expression (<xref ref-type="bibr" rid="bib16">Gareev et al., 2020</xref>). miRNAs regulate cell functions such as growth, differentiation, and energy metabolism by silencing the target gene via degradation or translational repression (<xref ref-type="bibr" rid="bib16">Gareev et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Wang et al., 2019b</xref>). Moreover, miRNAs are also involved in the pathophysiology of various inflammatory diseases and cancers (<xref ref-type="bibr" rid="bib29">Kumar et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Acunzo et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Gao et al., 2020</xref>). Certain miRNAs had been reported to regulate osteogenesis and bone homeostasis (<xref ref-type="bibr" rid="bib15">Gao et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Wang et al., 2019a</xref>). MicroRNA-155 (miR155) is one of the best conserved and multifunctional miRNAs that regulate several biological processes and diseases such as tumorigenesis, cardiovascular disease, kidney diseases, etc. (<xref ref-type="bibr" rid="bib13">Elton et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Readhead et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Bala et al., 2016</xref>; <xref ref-type="bibr" rid="bib61">Wu et al., 2018</xref>). miR155 is upregulated in inflammatory diseases and cancers, including periodontitis, lung cancer, liver cancer, and breast cancer (<xref ref-type="bibr" rid="bib62">Wu et al., 2021</xref>; <xref ref-type="bibr" rid="bib48">Shao et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Xin et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Pasculli et al., 2020</xref>). Systemic bone loss is frequently observed in patients with inflammatory diseases and cancers (<xref ref-type="bibr" rid="bib12">Dimitroulas et al., 2013</xref>; <xref ref-type="bibr" rid="bib4">Badri et al., 2019</xref>). However, the role of miR155 on osteogenesis and bone homeostasis is still unclear.</p><p>Induced osteoclasts formation/activity and compromised osteogenic differentiation disrupt bone homeostasis causing bone loss (<xref ref-type="bibr" rid="bib28">Kitaura et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2014</xref>). Osteoclast formation and activity are induced during inflammation and cancer (<xref ref-type="bibr" rid="bib2">Adamopoulos, 2018</xref>; <xref ref-type="bibr" rid="bib45">Roodman, 2001</xref>). <italic>Mir155</italic> had been reported to induce osteoclastogenesis (<xref ref-type="bibr" rid="bib25">Kagiya and Nakamura, 2013</xref>). <italic>Mir155</italic> knockout (<italic>Mir155</italic>-KO) mice exhibit reduced local bone destruction in arthritis attributed to reduced generation of osteoclasts (<xref ref-type="bibr" rid="bib6">Blüml et al., 2011</xref>). Osteogenic differentiation of precursor cells results in bone formation and is the key anabolic event of bone homeostasis. Reduced osteogenic differentiation of precursor cells causes low bone mass phenotype increasing the risk of fracture. Osteogenesis is also a key biological process of bone tissue engineering. Various miRNAs targeted approaches have been developed to promote bone regeneration and bone defect healing during bone tissue engineering (<xref ref-type="bibr" rid="bib3">Arriaga et al., 2019</xref>). The role of <italic>Mir155</italic> in osteogenic differentiation and bone regeneration has been rarely investigated. Compromised osteogenesis and low bone mass phenotype are frequently observed in patients with inflammatory diseases and cancers (<xref ref-type="bibr" rid="bib47">Schmidt et al., 2019</xref>; <xref ref-type="bibr" rid="bib37">Mann et al., 2009</xref>). Similarly, effective bone regeneration and bone defect healing are also key challenges in patients with inflammatory diseases. <italic>Mir155</italic> targets multiple genes to regulate the pathophysiology of a specific disease in a cell type-specific manner (<xref ref-type="bibr" rid="bib22">Hsin et al., 2018</xref>). Sphingosine 1-phosphate receptor-1 (<italic>S1pr1</italic>) is one of the target genes of <italic>Mir155</italic> (<xref ref-type="bibr" rid="bib65">Xin et al., 2015</xref>), which has been reported to positively regulate the osteogenic differentiation of precursor cells (<xref ref-type="bibr" rid="bib46">Sato et al., 2012</xref>; <xref ref-type="bibr" rid="bib20">Higashi et al., 2016</xref>). Therefore, it is wise to explore the involvement of <italic>S1pr1</italic> in the <italic>Mir155</italic>-mediated effect on osteogenesis.</p><p>In this study, we aimed to analyze the effect of different levels of <italic>Mir155</italic> on osteogenesis and bone mass phenotype using <italic>Mir155</italic> transgenic (<italic>Mir155</italic>-Tg) and <italic>Mir155</italic>-KO mice. This study also investigated the role of <italic>Mir155</italic> target gene <italic>S1pr1</italic> on the osteogenic differentiation of bone marrow stromal stem cells (BMSCs). We found a catabolic effect of <italic>Mir155</italic> on osteogenesis and bone mass phenotype by targeting the <italic>S1pr1</italic> gene.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Mir155</italic>-Tg mice showed a low bone mass phenotype</title><p>We analyzed the expression pattern of <italic>Mir155</italic>-Tg mice. <italic>Mir155</italic> expression was 8.57-fold higher in bone tissue of <italic>Mir155</italic>-Tg mice compared with the wild-type mice (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Hematoxylin and eosin (H&amp;E) staining shows the growth plate, trabecular bone, cortical bone, and marrow structure of <italic>Mir155</italic>-Tg and wild-type mice. Low trabecular density was observed in <italic>Mir155</italic>-Tg mice compared with wild-type mice (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Micro-CT results showed reduced cortical bone thickness and bone volume/total volume (BV/TV) in <italic>Mir155-Tg</italic> mice (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). The bone mineral density (BMD) level was not significantly changed (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Micro-CT images showed fewer and thinner trabeculae in <italic>Mir155</italic>-Tg mice femur compared with wild-type mice (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Trabecular bone parameter BV/TV, BMD, trabecular number (Tb.N), and trabecular thickness (Tb.Th) were significantly reduced in <italic>Mir155</italic>-Tg mice compared with wild-type mice (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). In <italic>Mir155</italic>-Tg mice, trabecular separation (Tb.Sp) was significantly increased compared with wild-type mice (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). These results indicate the low bone mass phenotype in <italic>Mir155</italic>-Tg mice.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Mir155</italic> transgenic (<italic>Mir155</italic>-Tg) mice showed a low bone mass phenotype.</title><p>(<bold>A</bold>) <italic>Mir155</italic> expression in bone, (<bold>B</bold>) <italic>Hematoxylin and eosin (H&amp;E) staining</italic>, (<bold>C</bold>) representative micro-CT images for cortical bone, (<bold>D</bold>) bone volume/total volume (BV/TV) and bone mineral density (BMD) analysis, (<bold>E</bold>) representative micro-CT images for trabecular bone, (<bold>F</bold>) BV/TV, BMD, trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp) analysis. Data are presented as mean ± SD, n=8. Significant difference compared to wild-type mice, *p&lt;0.05, **p&lt;0.01, and ****p&lt;0.0001.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig1">Figure 1A, D</xref> (BV/TV and BMD), and <xref ref-type="fig" rid="fig1">Figure 1F</xref> (BV/TV, BMD, Tb.N, Tb.Th, and Tb.Sp).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-77742-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig1-v2.tif"/></fig></sec><sec id="s2-2"><title><italic>Mir155</italic>-KO mice showed a high bone mass phenotype</title><p><italic>Mir155</italic> expression in <italic>Mir155</italic>-KO mice was dramatically downregulated compared with wild-type mice (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). H&amp;E staining demonstrated that trabeculae were increased in the <italic>Mir155</italic>-KO mice compared with wild-type mice (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Micro-CT results showed a higher cortical bone thickness and BV/TV in <italic>Mir155</italic>-KO mice (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). The BMD level was not significantly increased in <italic>Mir155</italic>-KO mice compared with wild-type (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Micro-CT images showed robustly dense and interconnected trabeculae in <italic>Mir155</italic>-KO mice compared with wild-type mice (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). The trabecular bone parameters BV/TV, BMD, and Tb.N in <italic>Mir155</italic>-KO mice were increased by 2-, 2.69-, and 1.83-fold respectively, compared with wild-type mice (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). While Tb.Th was similar in <italic>Mir155</italic>-KO and wild-type mice (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Tb.Sp in <italic>Mir155</italic>-KO mice was significantly reduced compared with wild-type mice (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). These results indicate the high bone mass phenotype of <italic>Mir155</italic>-KO mice. <italic>Mir155</italic>-KO and <italic>Mir155</italic>-Tg showed an opposite trend of bone mass phenotype and bone parameters (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>), suggesting the role of <italic>Mir155</italic> in bone homeostasis regulation.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Mir155</italic> knockout (<italic>Mir155</italic>-KO) mice showed a high bone mass phenotype.</title><p>(<bold>A</bold>) <italic>Mir155</italic> expression in bone, (<bold>B</bold>) Hematoxylin and eosin (H&amp;E) staining, (<bold>C</bold>) representative micro-CT images for cortical bone, (<bold>D</bold>) bone volume/total volume (BV/TV) and bone mineral density (BMD) analysis, (<bold>E</bold>) representative micro-CT images for trabecular bone, (<bold>F</bold>) BV/TV, BMD, trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp) analysis. Data are presented as mean ± SD, n=8. Significant difference compared to wild-type group, *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig2">Figure 2A, D</xref> (BV/TV and BMD), and <xref ref-type="fig" rid="fig2">Figure 2F</xref> (BV/TV, BMD, Tb.N, Tb.Th, and Tb.Sp).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-77742-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig2-v2.tif"/></fig></sec><sec id="s2-3"><title>Lipopolysaccharide-related osteolysis</title><p>We analyzed the effect of <italic>Mir155</italic>-KO in the context of inflammation-related bone loss. H&amp;E staining of long bone tissue sections showed more trabecular bone in lipopolysaccharide (LPS)-treated <italic>Mir155</italic>-KO mice compared with LPS-treated wild-type mice (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Micro-CT images showed slightly thicker cortical bone in LPS-treated <italic>Mir155</italic>-KO mice compared with LPS-treated wild-type mice (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Cortical bone parameters BV/TV and BMD were significantly increased in LPS-treated <italic>Mir155</italic>-KO mice compared with LPS-treated wild-type mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Micro-CT images showed more dense and interconnected trabeculae in LPS-treated <italic>Mir155</italic>-KO mice compared with LPS-treated wild-type mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). The trabecular bone parameters BV/TV, BMD, and Tb.N were increased by 2.3-, 1.22-, and 2.68-fold, respectively, in LPS-treated <italic>Mir155</italic>-KO mice compared with LPS-treated wild-type mice (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Tb.Sp was significantly decreased in LPS-treated <italic>Mir155</italic>-KO mice compared with LPS-treated wild-type mice (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). These results demonstrate the protective effect of <italic>Mir155</italic>-KO against LPS-induced bone loss.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Mir155</italic> knockout (<italic>Mir155</italic>-KO) mice showed higher resistance against lipopolysaccharide (LPS)-induced bone loss.</title><p>(<bold>A</bold>) Hematoxylin and eosin (H&amp;E) staining, (<bold>B</bold>) representative micro-CT images for cortical bone, (<bold>C</bold>) bone volume/total volume (BV/TV) and bone mineral density (BMD) analysis, (<bold>D</bold>) Representative micro-CT images for trabecular bone, (<bold>E</bold>) BV/TV, BMD, trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp) analysis. Data are presented as mean ± SD, n=6. Significant difference compared to wild-type group, *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig3">Figure 3C</xref> (BV/TV and BMD) and <xref ref-type="fig" rid="fig3">Figure 3E</xref> (BV/TV, BMD, Tb.N, Tb.Th, and Tb.Sp).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-77742-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig3-v2.tif"/></fig></sec><sec id="s2-4"><title>Ectopic bone regeneration was inhibited in <italic>Mir155</italic>-Tg mice while increased in <italic>Mir155</italic>-KO mice</title><p>A bone regeneration study was conducted to investigate whether the bone regeneration potential is altered in <italic>Mir155</italic>-Tg and <italic>Mir155</italic>-KO mice. BMP2-loaded collagen membranes were implanted in mice ectopically to confirm the bone regeneration potential in the ectopic site of <italic>Mir155</italic>-Tg, <italic>Mir155</italic>-KO, and the respective wild-type mice. Micro-CT images showed very less bone volume in collagen membrane transplanted in <italic>Mir155</italic>-Tg mice compared with that of wild-type mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The <italic>Mir155</italic>-Tg group showed significantly reduced BV/TV and Tb.N in newly formed bone compared with the wild-type group (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). Tb.Th and Tb.Sp levels were similar in the <italic>Mir155</italic>-Tg and wild-type groups (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>). In contrast, ectopic bone regeneration was significantly increased in the <italic>Mir155</italic>-KO group compared with the wild-type group (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Newly formed bone BV/TV and Tb.N in the <italic>Mir155</italic>-KO group were increased by 6.12- and 5.64-fold respectively compared with the wild-type group (<xref ref-type="fig" rid="fig4">Figure 4G and H</xref>). Tb.Th remained unchanged in <italic>Mir155</italic>-KO mice (<xref ref-type="fig" rid="fig4">Figure 4I</xref>) but the Tb.Sp was significantly reduced in the <italic>Mir155</italic>-KO group compared with the wild-type group (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). These results indicate a catabolic effect of <italic>Mir155</italic> on bone regeneration.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Ectopic bone regeneration was inhibited in <italic>Mir155</italic> transgenic (<italic>Mir155</italic>-Tg) mice but enhanced in <italic>Mir155</italic> knockout (<italic>Mir155</italic>-KO) mice.</title><p>(<bold>A</bold>) Representative micro-CT images. (<bold>B</bold>) Bone volume/total volume (BV/TV), (<bold>C</bold>) trabecular number (Tb.N), (<bold>D</bold>) trabecular thickness (Tb.Th), and (<bold>E</bold>) trabecular separation (Tb.Sp) analysis in <italic>Mir155</italic>-Tg and wild-type mice. (<bold>F</bold>) Representative micro-CT images. (<bold>G</bold>) BV/TV, (<bold>H</bold>) Tb.N, (<bold>I</bold>) Tb.Th, and (<bold>J</bold>) Tb.Sp analysis in <italic>Mir155</italic>-KO and wild-type mice. Data are presented as mean ± SD, n=4. Significant difference compared to wild-type group, *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig4">Figure 4B, E, G-J</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-77742-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig4-v2.tif"/></fig></sec><sec id="s2-5"><title><italic>Mir155</italic>-KO mice showed enhanced bone regeneration in an orthotopic model</title><p>We further added a low dose of BMP-2 to the collagen membrane and evaluated the bone regeneration in calvarial bone defect of <italic>Mir155</italic>-KO and wild-type mice. The defect area was covered with a robustly high amount of newly formed bone in <italic>Mir155</italic>-KO mice compared with wild-type mice (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). Furthermore, BV/TV, BMD, and Tb.N (<xref ref-type="fig" rid="fig5">Figure 5C–E</xref>) were enhanced while Tb.Th and Tb.Sp were reduced in <italic>Mir155</italic>-KO mice compared with wild-type mice (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>). These results from calvarial bone defect healing analysis showed promising bone regeneration effects of <italic>Mir155</italic>-KO.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>A higher degree of bone regeneration was observed in the calvarial defect of <italic>Mir155</italic> knockout (<italic>Mir155</italic>-KO) mice with a low dose of BMP2 treatment.</title><p>(<bold>A</bold>) Representative micro-CT images, (<bold>B</bold>) local micro-CT images in defects, (<bold>C</bold>) bone volume/total volume (BV/TV), (<bold>D</bold>) bone mineral density (BMD), (<bold>E</bold>) trabecular number (Tb.N), (<bold>F</bold>) trabecular thickness (Tb.Th), and (<bold>G</bold>) trabecular separation (Tb.Sp) analysis. Data are presented as mean ± SD, n=8. Significant difference compared to wild-type mice, *p&lt;0.05 and **p&lt;0.01.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig5">Figure 5C-G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-77742-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig5-v2.tif"/></fig></sec><sec id="s2-6"><title><italic>Mir155</italic> influences the osteogenic differentiation of BMSCs</title><p>To further confirm the regulatory role of <italic>Mir155</italic> on osteogenesis, we analyzed the osteogenic differentiation potential BMSCs isolated from <italic>Mir155</italic>-Tg, <italic>Mir155</italic>-KO, and the respective wild-type mice. Mineralized matrix deposition potential in BMSCs from <italic>Mir155</italic>-TG mice was substantially reduced compared with that of wild-type mice (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). Similarly, protein expression levels of osteogenic markers ALP and RUNX2 in BMSCs from <italic>Mir155</italic>-Tg mice were reduced compared with those of wild-type mice (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). These results indicate the compromised osteogenic differentiation potential of BMSCs from <italic>Mir155</italic>-Tg mice. In contrast, BMSCs from <italic>Mir155</italic>-KO mice showed robustly higher matrix mineralization potential compared to those of wild-type mice (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref>). The protein expression levels of osteogenic markers ALP were enhanced in BMSCs from <italic>Mir155</italic>-KO (<xref ref-type="fig" rid="fig6">Figure 6G and H</xref>). However, RUNX2 protein levels were not changed in BMSCs from <italic>Mir155</italic>-KO mice compared with those from wild-type mice. These results demonstrated the catabolic effect of <italic>Mir155</italic> in the osteogenic differentiation of BMSCs.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>Mir155</italic> transgenic (<italic>Mir155</italic>-Tg) and <italic>Mir155</italic> knockout (<italic>Mir155</italic>-KO) bone marrow stromal stem cells (BMSCs) showed an opposite trend of osteogenic differentiation.</title><p>(<bold>A</bold>) Alizarin red staining (ARS) images at day 10 of culture, (<bold>B</bold>) ARS quantification, n=4, (<bold>C</bold>) Western blot analysis of osteogenic markers, and (<bold>D</bold>) densitometry quantification of protein bands in Mir155-Tg BMSCs, n=3. (<bold>E</bold>) ARS images stained at day 10 of culture, (<bold>F</bold>) ARS quantification, n=4, (<bold>G</bold>) Western blot analysis of osteogenic markers, and (<bold>H</bold>) densitometry quantification of protein bands in <italic>Mir155</italic>-KO BMSCs, n=4. Data are presented as mean ± SD. Significant difference compared to wild-type mice, *p&lt;0.05, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig6">Figure 6B, D</xref> (ALP and RUNX2), <xref ref-type="fig" rid="fig6">Figure 6E, H</xref> (ALP and RUNX2); original blots for <xref ref-type="fig" rid="fig6">Figure 6C and G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77742-fig6-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig6-v2.tif"/></fig></sec><sec id="s2-7"><title><italic>Mir155</italic> knockdown promotes the osteogenic differentiation of BMSCs</title><p><italic>Mir155</italic> knockdown in BMSCs was used to further confirm the role of <italic>Mir155</italic> in osteogenic differentiation. <italic>Mir155</italic> sponge lentivirus treatment significantly reduced the expression of <italic>Mir155</italic> in BMSCs (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), indicating the successful knockdown of <italic>Mir155</italic>. Matrix mineralization was robustly increased in the <italic>Mir155</italic> sponge group compared with the negative control group (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>). Furthermore, similarly, the protein expression levels of osteogenic markers ALP and RUNX2 were robustly upregulated in the <italic>Mir155</italic> sponge group compared with the negative control group (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref>). Furthermore, sponging <italic>Mir155</italic> did not affect cell viability and expression of mesenchymal stem cell markers in BMSCs (<xref ref-type="fig" rid="fig7">Figure 7F and G</xref>). These results further confirm the catabolic effect of <italic>Mir155</italic> on the osteogenic differentiation of precursor cells.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title><italic>Mir155</italic> knockdown bone marrow stromal stem cells (BMSCs) showed higher osteogenic differentiation potential.</title><p>(<bold>A</bold>) Mir155 expression level, n=3, (<bold>B</bold>) Alizarin red staining (ARS) images stained at 21 days of culture, (<bold>C</bold>) ARS quantification, n=3, (<bold>D</bold>) Western blot analysis, (<bold>E</bold>) densitometry quantification of protein bands, n=3, (<bold>F</bold>) cell viability, n=3, and (<bold>G</bold>) Fluorescence activated cell sorting (FACS) analysis. Data are presented as mean ± SD. Significant difference compared to the negative control, *p&lt;0.05, **p&lt;0.01, and ****p&lt;0.0001. NC: negative control.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig7">Figure 7A, C, E</xref> (ALP and RUNX2), and <xref ref-type="fig" rid="fig7">Figure 7F</xref>; original blots for <xref ref-type="fig" rid="fig7">Figure 7D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77742-fig7-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig7-v2.tif"/></fig></sec><sec id="s2-8"><title><italic>Mir155</italic> targets the <italic>S1pr1</italic> gene to regulate the osteogenic differentiation of BMSCs</title><p>TargetScan prediction showed that the binding sites of <italic>Mir155</italic> on <italic>S1pr1</italic> were rather conserved in different species, such as human, mice, rat, rhesus, etc. (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). The sequences of seeding sites and mutant seeding sites of <italic>S1pr1</italic> are shown in <xref ref-type="fig" rid="fig8">Figure 8B</xref>. Luciferase reporter gene assay was performed to analyze the <italic>Mir155</italic> and <italic>S1pr1</italic> gene interaction (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). Our results showed that <italic>Mir155</italic> directly binds to the 3’UTR of the S1PR1 (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). Sponging <italic>Mir155</italic> robustly enhanced the protein level expression of the <italic>S1pr1</italic> gene in BMSCs (<xref ref-type="fig" rid="fig8">Figure 8D</xref>), confirming the interaction of <italic>Mir155</italic> and the <italic>S1pr1</italic> gene. <italic>S1pr1</italic> transfection in BMSCs robustly enhanced the matrix mineralization (<xref ref-type="fig" rid="fig8">Figure 8E and F</xref>). The protein expression level of S1PR1 was enhanced in lentivirus-mediated <italic>S1pr1</italic> overexpressed BMSCs (<xref ref-type="fig" rid="fig8">Figure 8G and H</xref>). This result indicates the efficacy of lentivirus-based <italic>S1pr1</italic> overexpression in BMSCs. The protein expression levels of ALP and RUNX2 were increased in <italic>S1pr1</italic> overexpressed BMSCs (<xref ref-type="fig" rid="fig8">Figure 8G and H</xref>). <italic>S1pr1</italic> overexpression in BMSCs by lentivirus did not affect cell viability and proliferation (<xref ref-type="fig" rid="fig8">Figure 8I</xref>). These results indicate that the <italic>Mir155</italic> targets the <italic>S1pr1</italic> gene to regulate the osteogenic differentiation of BMSCs.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title><italic>Mir155</italic> targets sphingosine 1-phosphate receptor-1 (S1PR1) to regulate the osteogenic differentiation of bone marrow stromal stem cells (BMSCs).</title><p>(<bold>A</bold>) The <italic>Mir155</italic> binding site of <italic>S1pr1</italic> in different species, (<bold>B</bold>) the wild and mutant binding site of <italic>S1pr1</italic> in mice. (<bold>C</bold>) Luciferase assay, n=4, (<bold>D</bold>) S1PR1 protein expression and densitometry quantification of protein bands, n=3, (<bold>E</bold>) Alizarin red staining (ARS) images stained at 21 days of culture, (<bold>F</bold>) ARS quantification, n=3, (<bold>G</bold>) Western blot analysis of osteogenic markers, (<bold>H</bold>) densitometry quantification of protein bands, n=3, and (<bold>I</bold>) cell viability analysis, n=4. Data are presented as mean ± SD. Significant difference compared to negative control, *p&lt;0.05 and **p&lt;0.01.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig8">Figure 8C, D, F, H and I</xref>; original blots for <xref ref-type="fig" rid="fig8">Figure 8D, G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77742-fig8-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig8-v2.tif"/></fig></sec><sec id="s2-9"><title><italic>Mir155</italic> influences osteoclastogenesis</title><p>The function of <italic>Mir155</italic> on osteoclastogenesis was further explored. Primary bone marrow monocytes were isolated and induced into bone marrow-derived macrophages (BMMs). The receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL) was further used for osteoclastogenic differentiation. Tartrate-resistant acid phosphatase (TRAP) staining showed that <italic>Mir155</italic>-KO reduced the osteoclast number (<xref ref-type="fig" rid="fig9">Figure 9A and B</xref>). Gene expression of osteoclastogenesis markers including receptor activator of NF-κB (<italic>Rank</italic>) and cathepsin K (<italic>Ctsk</italic>) was significantly reduced during the osteoclastogenic differentiation of <italic>Mir155</italic>-KO BMMs (<xref ref-type="fig" rid="fig9">Figure 9C</xref>). Furthermore, bone resorption-related C-terminal telopeptides of <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/collagen-type-1">type I collagen</ext-link> (CTX-1) level were significantly reduced while bone formation-related procollagen type I N-terminal pro-peptide (PINP) level was increased in serum of <italic>Mir155</italic>-KO mice compared with wild-type mice (<xref ref-type="fig" rid="fig9">Figure 9D</xref>). These results demonstrate that <italic>Mir155</italic>-KO has the potential inhibitory effect on osteoclastogenesis.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Bone marrow-derived macrophages (BMMs) from <italic>Mir155</italic> knockout (<italic>Mir155</italic>-KO) mice exhibited compromised osteoclastogenic differentiation.</title><p>(<bold>A</bold>) Tartrate-resistant acid phosphatase (TRAP) staining, (<bold>B</bold>) osteoclast number quantification, n=8, (<bold>C</bold>) osteoclastogenic markers expression, n=3, (<bold>D</bold>) C-terminal telopeptides of type I collagen (CTX-1), and procollagen type I N-terminal pro-peptide (PINP) serum level, n=6. Data are presented as mean ± SD. Significant difference compared to the negative control, *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig9">Figure 9B, C and D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-77742-fig9-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig9-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Differentiation of MSCs to osteoblasts is a vital event of bone regeneration. Differentiated osteoblasts deposit mineralized matrix and contribute to new bone formation. Various miRNAs have been reported to regulate osteogenesis and bone mass phenotype (<xref ref-type="bibr" rid="bib3">Arriaga et al., 2019</xref>). In this study, <italic>Mir155</italic>-Tg mice showed compromised bone regeneration and low bone mass phenotype. In contrast, <italic>Mir155</italic>-KO mice showed improved bone regeneration, higher bone mass phenotype, and a protective effect against inflammation-induced bone loss. BMSCs from <italic>Mir155</italic>-Tg and <italic>Mir155</italic>-KO mice showed compromised and robust osteogenic differentiation potential, respectively. <italic>Mir155</italic> knockdown also promoted osteogenic differentiation potential in BMSCs. These results indicate a catabolic effect of <italic>Mir155</italic> on bone regeneration and bone mass phenotype. Knockdown of <italic>Mir155</italic> in BMSCs robustly enhanced the protein level expression of S1PR1 and osteogenic regulator RUNX2, indicating S1PR1 as a target gene of <italic>Mir155</italic> in BMSCs to regulate osteogenic differentiation. <italic>S1pr1</italic> overexpression in BMSCs enhanced RUNX2 expression and osteogenic differentiation of BMSCs indicating the regulatory role of <italic>Mir155</italic>-S1PR1 interaction on osteogenesis (<xref ref-type="fig" rid="fig10">Figure 10</xref>).</p><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Scheme of <italic>Mir155</italic>-mediated regulation of osteogenesis.</title><p>S1P activates the sphingosine 1-phosphate receptor-1 (S1PR1), further increasing RUNX2 expression to regulate the osteogenic differentiation of MSCs into osteoblasts. <italic>Mir155</italic> inhibits this process by direct binding with 3’UTR <italic>S1pr1</italic> mRNAs. MSCs: mesenchymal stromal cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77742-fig10-v2.tif"/></fig><p>miRNAs/anti-miRNAs have been used for bone tissue engineering (<xref ref-type="bibr" rid="bib3">Arriaga et al., 2019</xref>). MiR26a (<xref ref-type="bibr" rid="bib53">Wang et al., 2015</xref>), anti-miR31 (<xref ref-type="bibr" rid="bib11">Deng et al., 2013</xref>), anti-miR34a (<xref ref-type="bibr" rid="bib9">Chen et al., 2020b</xref>), miR135 (<xref ref-type="bibr" rid="bib63">Xie et al., 2016</xref>), anti-miR138 (<xref ref-type="bibr" rid="bib14">Eskildsen et al., 2011</xref>), anti-miR146a (<xref ref-type="bibr" rid="bib64">Xie et al., 2017</xref>), miR148a (<xref ref-type="bibr" rid="bib31">Li et al., 2017</xref>), anti-miR221 (<xref ref-type="bibr" rid="bib69">Yeh et al., 2016</xref>), and anti-miR3555p <xref ref-type="bibr" rid="bib52">Tomé et al., 2011</xref> have shown an anabolic effect on osteogenic differentiation of precursor cells and bone regeneration. Most of the miRNAs/anti-miRNAs promote bone regeneration via the activation of the osteogenic master regulator RUNX2 (<xref ref-type="bibr" rid="bib3">Arriaga et al., 2019</xref>). In this study, <italic>Mir155</italic> overexpression showed a catabolic effect on osteogenesis and bone mass phenotype. Interestingly, knockout or knockdown of <italic>Mir155</italic> showed an anabolic effect on osteogenesis, bone regeneration, and bone defect healing. RUNX2 was involved in the <italic>Mir155</italic>-mediated regulation of osteogenic differentiation of BMSCs. RUNX2 expression did not change in <italic>Mir155</italic>-KO BMSCs but was upregulated in <italic>Mir155</italic> sponged BMSCs from wild-type mice. Whole body knockout of <italic>Mir155</italic> also knock outs the <italic>Mir155</italic> in the other cell types present in bone microenvironment, for example, monocytes and macrophages. The <italic>Mir155</italic>-KO BMSCs might have certain effects of surrounding <italic>Mir155</italic>-KO other cell types on S1PR1 expression, while the <italic>Mir155</italic> sponged BMSCs from wild-type mice sorted with FACS may be free from such effects. This could be the possible explanation for the lack of change in RUNX2 expression in <italic>Mir155</italic>-KO BMSCs, but rather an upregulation of RUNX2 expression in <italic>Mir155</italic> sponged BMSCs from wild-type mice observed in this study. However, further studies are required to support this logic. <italic>Mir155</italic> had been reported to inhibit osteogenesis of MC3T3-E1 cells via SMAD5 downregulation (<xref ref-type="bibr" rid="bib17">Gu et al., 2017</xref>). <italic>Mir155</italic> inhibits BMP9-induced osteogenic differentiation of precursor cells via downregulation of BMP signaling (<xref ref-type="bibr" rid="bib36">Liu et al., 2018</xref>). Qu et al. revealed that miR155 inhibition alleviates high glucose and free fatty acid-suppressed osteogenic differentiation of BMSCs by targeting SIRT1 (<xref ref-type="bibr" rid="bib42">Qu et al., 2020</xref>). Our results from <italic>Mir155</italic>-Tg mice on inhibition of osteogenesis are in accordance with the findings from the literature (<xref ref-type="bibr" rid="bib17">Gu et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Liu et al., 2018</xref>). Furthermore, <italic>Mir155</italic>-KO inhibited the osteoclastogenic differentiation of BMMs. To our knowledge, this is the first study to report the anabolic effect of <italic>Mir155</italic>-KO or knockdown on osteogenic differentiation and the catabolic effect of <italic>Mir155</italic>-KO on osteoclastogenesis. Our results suggest the potential application of anti-miR155 on bone regeneration and bone tissue engineering applications.</p><p>Anti-miR155 oligonucleotides and antagomir have been designed for various cancer treatments (<xref ref-type="bibr" rid="bib26">Kardani et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Witten and Slack, 2020</xref>). Small molecule-based cyclic peptidomimetics had shown an inhibitory effect on miR155 biogenesis (<xref ref-type="bibr" rid="bib67">Yan et al., 2019</xref>). MLN4924 is an inhibitor of the NEDD8-activating enzyme. MLN4924 decreases the binding of NF-κB to the miR155 promoter and downregulates miR155 in AML cells (<xref ref-type="bibr" rid="bib27">Khalife et al., 2015</xref>). Since the knockout of <italic>Mir155</italic> promoted bone regeneration and protected against inflammation-induced bone loss, anti-Mir155 or Mir155 inhibitors could be applied for bone tissue engineering and the treatment of low bone mass phenotype and inflammation-related bone loss. However, the osteoinductive potential of already available anti-<italic>Mir155</italic> or <italic>Mir155</italic> inhibitors should be tested using in vitro and in vivo models to prove this hypothesis.</p><p>miR155 targets different genes in different cells to regulate the cell type-specific functions (<xref ref-type="bibr" rid="bib60">Woeller et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Hawez et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 2021c</xref>). <italic>S1pr1</italic>, a target gene of <italic>Mir155</italic>, is regulated during various physiological and pathological conditions (<xref ref-type="bibr" rid="bib34">Li et al., 2021c</xref>; <xref ref-type="bibr" rid="bib39">Okoye et al., 2014</xref>). TargetScan prediction results showed that the binding site of <italic>Mir155</italic> on <italic>S1pr1</italic> was rather conserved in several different species such as human, rat, mouse, etc. In this study, <italic>Mir155</italic> inhibition upregulated S1PR1 protein expression. Overexpression of <italic>S1pr1</italic> robustly promoted RUNX2 protein expression and osteogenic differentiation of BMSCs. <italic>Mir155</italic> has been shown to inhibit the osteogenic differentiation of precursor cells via inhibiting SMAD5 (<xref ref-type="bibr" rid="bib17">Gu et al., 2017</xref>). Higashi et al. reported SMAD1/5/8 as downstream signaling of S1PR1/S1PR2 to induce RUNX2 expression in osteoblasts (<xref ref-type="bibr" rid="bib20">Higashi et al., 2016</xref>). Reports from the literature and results of this study indicate that <italic>Mir155</italic> targets the <italic>S1pr1</italic> gene to inhibit RUNX2 expression thereby reducing bone regeneration and bone mass.</p><p>Since miR155 is upregulated in various cancers including hematological cancers (<xref ref-type="bibr" rid="bib59">Witten and Slack, 2020</xref>). Hematological cancer mainly affects bone marrow which is the dwelling of bone precursor cells. Hematological cancers are associated with bone loss and fracture of vertebrae and long bones. Breast and lung cancer are frequently metastasized to bone and cause osteolysis (<xref ref-type="bibr" rid="bib40">Pang et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Cheng et al., 2021</xref>). Cancer/cancer metastasis-induced bone loss-mediated fracture is a serious clinical problem. However, the role of upregulated levels of miR155 on cancer/cancer metastasis-related reduced bone mass is still unclear. Moreover, the prevention of cancer/cancer metastasis-induced bone loss is a huge challenge for clinicians. Since anti-miR155 has already been proven to be beneficial for cancer treatment and miR155 knockdown promotes bone regeneration, anti-miR155 could treat cancer as well as caner-induced bone loss as a killing two birds with one stone concept. However, future in vitro and in vivo studies are needed to confirm this hypothesis.</p><p>Mir155 is overexpressed and plays a key role in the pathophysiology of inflammatory diseases including autoimmune arthritis, osteoarthritis, and periodontitis (<xref ref-type="bibr" rid="bib62">Wu et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Blüml et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Li et al., 2021a</xref>). An elevated level of <italic>Mir155</italic> in arthritis promotes M1 macrophage polarization and inflammation (<xref ref-type="bibr" rid="bib32">Li et al., 2021a</xref>). Prevention of bone loss in inflammatory diseases using currently available therapeutic approaches is not satisfactory. Moreover, inflammation impedes bone regeneration thereby causing the failure of bone tissue engineering approaches. In the present study, we found that <italic>Mir155</italic>-KO exerts a protective effect against LPS-induced bone loss. Since anti-<italic>Mir155</italic> has anti-inflammatory (<xref ref-type="bibr" rid="bib50">Teng et al., 2020</xref>) and bone regenerative potential, anti-<italic>Mir155</italic> could be a potential therapeutic to prevent inflammation-induced bone loss.</p><p>This study used both <italic>Mir155</italic>-Tg and <italic>Mir155</italic>-KO mice to investigate the role of <italic>Mir155</italic> on osteogenesis and bone mass phenotype. Bone regeneration in both ectopic and orthotopic models confirmed the regulatory role of <italic>Mir155</italic> in bone regeneration. <italic>Mir155</italic> silenced and <italic>S1pr1</italic> overexpressed BMSCs further confirmed the <italic>S1pr1</italic> as a target gene of <italic>Mir155</italic> to regulate RUNX2 expression during osteogenesis. The limitation of this study is that we did not analyze the downstream signaling pathway of S1PR1 that regulates RUNX2 expression in BMSCs. Clinical application of osteogenic factors in vivo always poses the risk of vascular calcification. miR155-5p overexpression has been reported to aggravate vascular calcification (<xref ref-type="bibr" rid="bib19">He et al., 2020</xref>). Importantly, <italic>Mir155</italic>-KO mice also show resistance against vitamin D3-induced vascular calcification (<xref ref-type="bibr" rid="bib33">Li et al., 2021b</xref>). Moreover, <italic>Mir155</italic> deletion inhibits the migration and apoptosis of vascular smooth muscle cells as well as vascular calcification (<xref ref-type="bibr" rid="bib33">Li et al., 2021b</xref>). Furthermore, Zhang et al. showed normal histology of vital organs including the heart, lung, liver, and spleen in <italic>Mir155</italic>-KO mice (<xref ref-type="bibr" rid="bib70">Zhang et al., 2017</xref>). These reports from the literature indicate that <italic>Mir155</italic>-KO does not pose the risk of vascular calcification. However, the effect of <italic>Mir155</italic> inhibitors or anti-<italic>Mir155</italic> on vascular calcification should be thoroughly investigated before applying these agents for bone regeneration applications.</p><p>In conclusion, <italic>Mir155</italic> showed a catabolic effect on osteogenesis and bone mass via targeting <italic>S1pr1</italic>. Our results suggest miR155 as a potential target to promote bone regeneration and higher bone mass. Since miR155 is overexpressed in inflammatory diseases and anti-miR155 has shown anti-inflammatory potential, the miR15<italic>5</italic> inhibitors could be the potential therapeutics to promote bone regeneration even in inflammatory conditions.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p><italic>Mir155</italic>-KO mice were purchased from the Jackson Laboratory (Stock No. 007745). <italic>Mir155</italic>-Tg mice were constructed as described in our previous reports (<xref ref-type="bibr" rid="bib35">Lin et al., 2016</xref>). The C57BL/6J wild-type mice, as the wild-type mice of <italic>Mir155</italic>-KO mice, were purchased from Guangdong Medical Laboratory Animal Center. While the FVB mice were a littermate control of <italic>Mir155</italic>-Tg mice. The blinded evaluation was used for mice assignments and analysis. The animal experiment was conducted in accordance with the guidelines approved by the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (2017-078).</p></sec><sec id="s4-2"><title>Bone phenotype analysis</title><p>Bone phenotype analysis was performed in 8-week-old mice (8 mice/group including 4 male and 4 female mice) using micro-CT. Mice were anesthetized using isoflurane (RWD Life Science Co., China), followed by cervical dislocation. The femur with a distal growth plate was collected and fixed in 10% buffered formalin. Micro-CT scanning was performed to evaluate bone phenotype using Bruker Sky1172 Skyscan (Kontich, Belgium). A total of 100 slices (1 mm) below the distal growth plate of the femurs was measured for 3D reconstruction and quantification of trabecular bone and cortical bone as described previously (<xref ref-type="bibr" rid="bib38">Moussa et al., 2021</xref>). The X-ray tube was operated at 96 kV and 65 μA using a 0.5 mm Al filter with a resolution of 7.93 μm pixels. Scanning was performed by 180° rotation around the vertical axis, camera exposure time of 1300 ms, rotation step of 0.6°, frame averaging of 2, and random movement of 10. 3D images were made using CTvox software (Skyscan, Kontich, Belgium). Data viewer software (Skyscan, Kontich, Belgium) was used for images and linear analysis. Relative bone formation parameters including BV/TV, BMD, Tb.N, Tb.Th, and Tb.Sp were analyzed.</p></sec><sec id="s4-3"><title>LPS-treated mice</title><p>As reported by <xref ref-type="bibr" rid="bib8">Chen et al., 2020a</xref>, wild-type mice and Mir155-KO mice (6 mice/group including 3 male mice and 3 female mice) were injected intraperitoneally with LPS (8 mg/kg) twice 1 week. Mice were weighed before LPS injection. After 6 weeks, femurs were collected for micro-CT analysis and H&amp;E staining.</p></sec><sec id="s4-4"><title>H&amp;E staining</title><p>H&amp;E staining for bone tissues was performed as previously reported (<xref ref-type="bibr" rid="bib8">Chen et al., 2020a</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2018</xref>). Femurs were fixed in 4% PFA for 2 days and decalcified with EDTA decalcified solution for 21 days. After that, femurs were cut for histological analysis, the femurs were dissected and conducted in 4% PFA for 2 days. Then slices of bone tissue at 3 μm thickness were cut along the coronal plate. The decalcified slices were further performed H&amp;E staining by dewaxing, hematoxylin staining, eosin staining, and dehydration.</p></sec><sec id="s4-5"><title>Ectopic grafting of collagen membrane</title><p>The subcutaneous transplantation of the collagen membrane was performed as described previously (<xref ref-type="bibr" rid="bib23">Huang et al., 2017</xref>). Collagen membrane ZH-BIO (China) with 5 mm diameter and 1 mm thickness were osteogenically functionalized by loading 10 μL of 0.3 mg/mL BMP2 solution. BMP2-loaded collagen membranes were implanted in the subcutaneous pockets of <italic>Mir155</italic>-Tg, <italic>Mir155</italic>-KO, and respective wild-type mice. Eight-week-old male mice with 20–22 g body weight (4 mice/group, 1 membrane/mouse) were used for this study. After 18 days of transplantation, mice were euthanized by isoflurane, collagen membrane was collected and further analyzed for newly formed bone using micro-CT.</p></sec><sec id="s4-6"><title>Mice calvaria bone defect healing with BMP2 addition</title><p>As previously reported (<xref ref-type="bibr" rid="bib44">Reyes et al., 2018</xref>), a 3 mm diameter was generated on one side of the sagittal suture in 8-week <italic>Mir155</italic>-KO mice and wild-type mice (8 mice/group including 4 male mice and 4 female mice, 1 defect/mouse). A total of 200 ng BMP2 (10 μL) was dropped into the collagen membrane ZH-BIO (China). The membrane was inserted into the defect. Calvaria bones were collected and analyzed by micro-CT after 1 month.</p></sec><sec id="s4-7"><title>The isolation of primary BMSCs and osteoclastogenic induction</title><p>Euthanized transgenic mice and wild-type male mice (5–6 weeks of age) were immersed into 75% ethanol for 5 min. The femurs and tibia were acquired. Primary BMSCs were isolated and expanded as described previously (<xref ref-type="bibr" rid="bib49">Soleimani and Nadri, 2009</xref>). In brief, bone marrow was flushed out from the tibia and femurs and disturbed into small pieces. Cells were collected by centrifugation and plated into flasks and allowed to adhere for 24 hr. Nonadherent cells were washed, and culture was continued in DMEM supplemented with 10% non-heat inactivated FBS and 1% penicillin/streptomycin. The cells were cultured in a 5% CO<sub>2</sub> incubator maintaining a humid atmosphere. Cells were trypsinized from 80% confluent culture and passaged.</p></sec><sec id="s4-8"><title>Analysis of the target gene of <italic>Mir155</italic></title><p>TargetScan software was used to predict the target gene of <italic>Mir155</italic>. TargetScan predicted S1PR1 as a possible target gene of <italic>Mir155</italic>.</p></sec><sec id="s4-9"><title>Plasmid construction and lentivirus preparation</title><p>The <italic>S1pr1</italic> 3’UTR sequences and mutant sequences (200 bp upstream and 200 bp downstream of the binding site from <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007901.5">NM_007901.5</ext-link> transcript) were synthesized and cloned into wild-type plasmid pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, USA) by Generay (China). We created <italic>S1pr1</italic> 3’UTR and <italic>S1pr1</italic> mutant 3’UTR plasmids for luciferase assay. The LV242 <italic>S1pr1</italic> and control LV242 plasmid were purchased from Genecopedia (USA). <italic>Mir155</italic> negative control (NC) and <italic>Mir155</italic> sponge plasmids were purchased from OBIO (China).</p><p>As previously described (<xref ref-type="bibr" rid="bib72">Zheng et al., 2013</xref>), HEK293T cells were co-transfected with expression plasmids (<italic>Mir155</italic> NC, <italic>Mir155</italic> sponge, LV242, or LV242 <italic>S1pr1</italic>) with the packaging plasmids pMD2.VSVG, pMDLg/pRRE, and pRSV-REV using EZ trans transfection regent (Shanghai life iLab BioTechnology Co., Ltd., China). After 48 hr, fresh lentiviral supernatant was collected and used for infection. BMSCs were expanded to 60% confluence before lentiviral infection. After infection for 10 hr, cells were washed and allowed to recover for 24 hr and used for subsequent experiments. <italic>Mir155</italic> sponge efficacy was analyzed by RT-qPCR. S1PR1 overexpression efficacy was analyzed by Western blot analysis.</p></sec><sec id="s4-10"><title>Luciferase assay</title><p>Luciferase assay was performed as previously described (<xref ref-type="bibr" rid="bib57">Wang et al., 2019c</xref>). Luciferase assay was performed for further confirmation of <italic>S1pr1</italic> as a target gene of <italic>Mir155</italic>. S1PR1 3’UTR (100 ng) with NC (50 nM), <italic>S1pr1</italic> 3’UTR (100 ng) with <italic>Mir155</italic> (50 nM), and the <italic>S1pr1</italic> mutant 3’UTR plasmid (100 ng) with <italic>Mir155</italic> (50 nM) were co-transfected into HEK293T cells by Lipofectamine 2000 (Thermo Fisher Scientific Inc, USA). After 48 hr, the luciferase assay was performed according to the manufacturer’s instructions using Luc-Pair Duo-Luciferase Assay Kit 2.0 (GeneCopoeia, USA). In brief, the cells were lysed and incubated with 100 μL Fluc work solution for 5 min, the fluorometric measurement was performed by Varioskan Flash (Thermo Fisher, USA). The lysis solution was added with 100 μL Rluc, incubated for 5 min, and the fluorometric value was measured.</p></sec><sec id="s4-11"><title>Alizarin red staining</title><p>Alizarin red staining was performed as a previous report (<xref ref-type="bibr" rid="bib58">Wang et al., 2022</xref>). BMSCs (28,000 cells/well) were seeded at 48-well culture plates and cultured with osteogenic medium (50 μg/mL vitamin C, 0.01 μM dexamethasone, and 10 mM β-glycerophosphate). Then, the cells were fixed with paraformaldehyde and stained with Alizarin Red S solution (1%, pH 4.2) (Solarbio Life Science, China) for 10 min. The staining was visualized under stereomicroscope Leica EZ4HD (Leica, Germany). For quantitative analysis, the alizarin red-stained mineralized matrix was dissolved with 200 μL 10% hexadecylpyridinium chloride monohydrate for 1 hr, and the supernatant was collected. The optical density of the supernatant (100 μL) was measured by a microplate reader at 562 nm.</p></sec><sec id="s4-12"><title>Immunoblotting</title><p>Immunoblotting was performed as a previous report (<xref ref-type="bibr" rid="bib71">Zhang et al., 2021</xref>). Cells were lysed by using RIPA Buffer (CWBio, China) containing protease inhibitors to extract total protein. Total protein (20 μg) was added to 10% SDS-polyacrylamide gel. The protein was transferred to PVDF membranes (Millipore, USA) after electrophoresis and blocked for 1 hr with a blocking buffer (Beyotime, China). Then PVDF membranes were incubated with the primary antibodies including ALP (Abcam, UK, 1:3000), RUNX2 (CST, USA, 1:2,000), S1PR1 (Abcam, UK, 1:2,000), and GAPDH (CST, USA, 1:5,000) overnight at 4°C. The membranes were further incubated with horseradish peroxidase-conjugated secondary antibody for 1 hr and reacted with ECL (Millipore, USA). Finally, the photographs were taken by Tanon-5200 system (Tanon, China). The densitometry of protein bands was quantified by ImageJ 1.51K.</p></sec><sec id="s4-13"><title>RT-qPCR</title><p>The femurs were collected from wild-type, <italic>Mir155</italic>-Tg, and <italic>Mir155</italic>-KO mice. And bones were ground with a high-speed low-temperature tissue homogenizer (Servicebio, China). As previously reported (<xref ref-type="bibr" rid="bib51">Teng et al., 2022</xref>), the miRNAs were extracted from BMSCs and ground bone tissues with the MolPure Cell/Tissue miRNA Kit (Yeasen, China) as per the manufacturer’s instructions. The miRNA was further reversed by Tailing reaction using miRNA first strand cDNA synthesis kit (Accurate Biology, China). In brief, 3.75 μL miRNA, 5 μL 2×miRNA RT Reaction Solution, 1.25 μL miRNA RT Enzyme Mix were incubated at 37°C for 1 hr, 85°C for 5 min. The mRNAs from osteoclasts induced from <italic>Mir155</italic>-KO and wild-type mice were extracted with an RNA extraction kit (Accurate Biology, China) as per the manufacturer’s instruction. Total RNA (500 ng) was transcribed with reversed regents (Accurate Biology, China). RT-qPCR was performed using <ext-link ext-link-type="uri" xlink:href="https://agbio.com.cn/product/sybr-green-premix-pro-taq-hs-qpcr-kit-%ef%bc%88rox-plus%ef%bc%89/?v=b838b393d55f">SYBR Green Premix Pro Taq HS qPCR Kit</ext-link> (Accurate Biology, China) on an AriaMx Real-time quantitative PCR machine (Agilent, USA). The PCR conditions were 95°C for 30 s, followed by 40 cycles at 95°C for 5 s and 60°C for 30 s. The fold change relative to the control group was measured by the 2<sup>-∆∆Ct</sup> method. The primers used were shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Primers used for RT-qPCR.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene name</th><th align="left" valign="bottom">Forward sequence (5’-&gt;3’)</th><th align="left" valign="bottom">Reversed sequence (5’-&gt;3’)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>Gapdh</italic></td><td align="left" valign="bottom">TGTGTCCGTCGTGGATCTG</td><td align="left" valign="bottom">TTGCTGTTGAAGTCGCAGGA</td></tr><tr><td align="left" valign="bottom"><italic>Rank</italic></td><td align="left" valign="bottom">CCAGGAGAGGCATTATGAGCA</td><td align="left" valign="bottom">ACTGTCGGAGGTAGGAGTGC</td></tr><tr><td align="left" valign="bottom"><italic>Ctsk</italic></td><td align="left" valign="bottom">FCTCGGCGTTTAATTTGGGAGA</td><td align="left" valign="bottom">TCGAGAGGGAGGTATTCTGAGT</td></tr><tr><td align="left" valign="bottom"><italic>Mir155</italic></td><td align="center" valign="bottom" colspan="2">5’-TAATGCTAATTGTGATAGGGGT-3’</td></tr></tbody></table></table-wrap></sec><sec id="s4-14"><title>PrestoBlue cell viability assay</title><p>Cell viability was analyzed using PrestoBlue cell viability reagent (Thermo Fisher, USA) (<xref ref-type="bibr" rid="bib24">Jaafar et al., 2019</xref>). BMSCs (4×10<sup>3</sup> cells/well) were seeded into 96-well culture plates. After 1, 3, and 5 days, the medium was removed and replaced with a cell viability detection medium according to the manufacturer’s instructions. After 2 hr, the OD value was measured by a microplate reader at 570 nm with a reference wavelength of 600 nm.</p></sec><sec id="s4-15"><title>TRAP staining</title><p>TRAP staining was performed as previously reported (<xref ref-type="bibr" rid="bib21">Ho et al., 2017</xref>). For osteoclastogenic differentiation, bone marrow cells were cultured in α-minimum essential medium containing 10% fetal bovine serum and added with M-CSF (10 ng/mL) for 4 days. Cells (8×10<sup>4</sup> cells/well) was supplemented with M-CSF (20 ng/mL) and RANKL (25 ng/mL) for 7 days. TRAP staining was performed with Acid Phosphatase, Leukocyte (TRAP) Kit as the manufacturer’s introduction (Sigma, USA).</p></sec><sec id="s4-16"><title>ELISA</title><p>Serum PINP and CTX-1 are essential markers for evaluating the level of bone resorption (<xref ref-type="bibr" rid="bib68">Ye et al., 2021</xref>). The levels of PINP and CTX-1 were measured using the PINP ELISA kit (SAB, USA) and CTX-1 ELISA kit (Finebio, China) as the manufacturer’s introduction.</p></sec><sec id="s4-17"><title>FACS analysis</title><p>FACS analysis was performed as previously reported (<xref ref-type="bibr" rid="bib73">Zhu et al., 2010</xref>). For cell surface staining, Sca-I (1:1000, eBioscience, USA), CD44 (1:1000, eBioscience, USA), CD11b (1:1000, eBioscience, USA), and CD31 (1:200, eBioscience, USA) were used.</p></sec><sec id="s4-18"><title>Statistical analysis</title><p>Data are expressed as mean ± SD. Statistical analysis was performed with t-tests for the comparison of the two groups. p&lt;0.05 was considered a significant difference.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Funding acquisition, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Visualization</p></fn><fn fn-type="con" id="con11"><p>Resources</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Supervision, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Data curation, Supervision, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The animal experiment was conducted in accordance with the guidelines approved by the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (2017-078).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-77742-transrepform1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Source data files have been provided as Figure 1-source data 1, Figure 2-source data 1, Figure 3-source data 1, Figure 4-source data 1, Figure 5-source data 1, Figure 6-source data 1, Figure 7-source data 1, Figure 8-source data 1, Figure 9-source data 1.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This project was funded by the Science and Technology program of Guangzhou (202201010073, 202201020116), the National Natural Science Foundation of China (U22A20159, 82150410451), the General Guiding Project of Guangzhou (20201A011105), the Medical Scientific Research Foundation of Guangdong Province (B2020027), the Undergraduate Science and Technology Innovation Project of Guangzhou Medical University (2020A049), and High-level University Construction Funding of Guangzhou Medical University (02-412-B205002-1003017 and 06-410-2106035).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acunzo</surname><given-names>M</given-names></name><name><surname>Romano</surname><given-names>G</given-names></name><name><surname>Wernicke</surname><given-names>D</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Microrna and cancer -- a brief overview</article-title><source>Advances in Biological Regulation</source><volume>57</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jbior.2014.09.013</pub-id><pub-id pub-id-type="pmid">25294678</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamopoulos</surname><given-names>IE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inflammation in bone physiology and pathology</article-title><source>Current Opinion in Rheumatology</source><volume>30</volume><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1097/BOR.0000000000000449</pub-id><pub-id pub-id-type="pmid">29016371</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arriaga</surname><given-names>MA</given-names></name><name><surname>Ding</surname><given-names>MH</given-names></name><name><surname>Gutierrez</surname><given-names>AS</given-names></name><name><surname>Chew</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The application of micrornas in biomaterial scaffold-based therapies for bone tissue engineering</article-title><source>Biotechnology Journal</source><volume>14</volume><elocation-id>e1900084</elocation-id><pub-id pub-id-type="doi">10.1002/biot.201900084</pub-id><pub-id pub-id-type="pmid">31166084</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badri</surname><given-names>S</given-names></name><name><surname>Salawu</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bone health in men with prostate cancer: review article</article-title><source>Current Osteoporosis Reports</source><volume>17</volume><fpage>527</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1007/s11914-019-00536-8</pub-id><pub-id pub-id-type="pmid">31760582</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bala</surname><given-names>S</given-names></name><name><surname>Csak</surname><given-names>T</given-names></name><name><surname>Saha</surname><given-names>B</given-names></name><name><surname>Zatsiorsky</surname><given-names>J</given-names></name><name><surname>Kodys</surname><given-names>K</given-names></name><name><surname>Catalano</surname><given-names>D</given-names></name><name><surname>Satishchandran</surname><given-names>A</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis</article-title><source>Journal of Hepatology</source><volume>64</volume><fpage>1378</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.01.035</pub-id><pub-id pub-id-type="pmid">26867493</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blüml</surname><given-names>S</given-names></name><name><surname>Bonelli</surname><given-names>M</given-names></name><name><surname>Niederreiter</surname><given-names>B</given-names></name><name><surname>Puchner</surname><given-names>A</given-names></name><name><surname>Mayr</surname><given-names>G</given-names></name><name><surname>Hayer</surname><given-names>S</given-names></name><name><surname>Koenders</surname><given-names>MI</given-names></name><name><surname>van den Berg</surname><given-names>WB</given-names></name><name><surname>Smolen</surname><given-names>J</given-names></name><name><surname>Redlich</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice</article-title><source>Arthritis and Rheumatism</source><volume>63</volume><fpage>1281</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1002/art.30281</pub-id><pub-id pub-id-type="pmid">21321928</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Che</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SIKVAV-modified chitosan hydrogel as a skin substitutes for wound closure in mice</article-title><source>Molecules</source><volume>23</volume><elocation-id>2611</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23102611</pub-id><pub-id pub-id-type="pmid">30314388</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Epothilone B prevents lipopolysaccharide-induced inflammatory osteolysis through suppressing osteoclastogenesis via STAT3 signaling pathway</article-title><source>Aging</source><volume>12</volume><fpage>11698</fpage><lpage>11716</lpage><pub-id pub-id-type="doi">10.18632/aging.103337</pub-id><pub-id pub-id-type="pmid">32527985</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Xian</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Inhibition of mir‑155‑5p attenuates the valvular damage induced by rheumatic heart disease</article-title><source>International Journal of Molecular Medicine</source><volume>45</volume><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2019.4420</pub-id><pub-id pub-id-type="pmid">31894293</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>Q</given-names></name><name><surname>Xing</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials</article-title><source>Drug Delivery</source><volume>28</volume><fpage>37</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1080/10717544.2020.1856225</pub-id><pub-id pub-id-type="pmid">33336610</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>D</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The role of mir-31-modified adipose tissue-derived stem cells in repairing rat critical-sized calvarial defects</article-title><source>Biomaterials</source><volume>34</volume><fpage>6717</fpage><lpage>6728</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.05.042</pub-id><pub-id pub-id-type="pmid">23768901</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitroulas</surname><given-names>T</given-names></name><name><surname>Nikas</surname><given-names>SN</given-names></name><name><surname>Trontzas</surname><given-names>P</given-names></name><name><surname>Kitas</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Biologic therapies and systemic bone loss in rheumatoid arthritis</article-title><source>Autoimmunity Reviews</source><volume>12</volume><fpage>958</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2013.03.015</pub-id><pub-id pub-id-type="pmid">23542506</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elton</surname><given-names>TS</given-names></name><name><surname>Selemon</surname><given-names>H</given-names></name><name><surname>Elton</surname><given-names>SM</given-names></name><name><surname>Parinandi</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulation of the MIR155 host gene in physiological and pathological processes</article-title><source>Gene</source><volume>532</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2012.12.009</pub-id><pub-id pub-id-type="pmid">23246696</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eskildsen</surname><given-names>T</given-names></name><name><surname>Taipaleenmäki</surname><given-names>H</given-names></name><name><surname>Stenvang</surname><given-names>J</given-names></name><name><surname>Abdallah</surname><given-names>BM</given-names></name><name><surname>Ditzel</surname><given-names>N</given-names></name><name><surname>Nossent</surname><given-names>AY</given-names></name><name><surname>Bak</surname><given-names>M</given-names></name><name><surname>Kauppinen</surname><given-names>S</given-names></name><name><surname>Kassem</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Microrna-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo</article-title><source>PNAS</source><volume>108</volume><fpage>6139</fpage><lpage>6144</lpage><pub-id pub-id-type="doi">10.1073/pnas.1016758108</pub-id><pub-id pub-id-type="pmid">21444814</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Qian</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of micrornas in bone metabolism and disease</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21176081</pub-id><pub-id pub-id-type="pmid">32846921</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gareev</surname><given-names>I</given-names></name><name><surname>Beylerli</surname><given-names>O</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Pavlov</surname><given-names>V</given-names></name><name><surname>Izmailov</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The current state of miRNAs as biomarkers and therapeutic tools</article-title><source>Clinical and Experimental Medicine</source><volume>20</volume><fpage>349</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1007/s10238-020-00627-2</pub-id><pub-id pub-id-type="pmid">32399814</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mir-155 inhibits mouse osteoblast differentiation by suppressing Smad5 expression</article-title><source>BioMed Research International</source><volume>2017</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1155/2017/1893520</pub-id><pub-id pub-id-type="pmid">28473977</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawez</surname><given-names>A</given-names></name><name><surname>Al-Haidari</surname><given-names>A</given-names></name><name><surname>Madhi</surname><given-names>R</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Thorlacius</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mir-155 regulates PAD4-dependent formation of neutrophil extracellular traps</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>2462</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02462</pub-id><pub-id pub-id-type="pmid">31736940</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Indoxyl sulfate promotes osteogenic differentiation of vascular smooth muscle cells by mir-155-5p-dependent downregulation of matrix gla protein via ROS/NF-κB signaling</article-title><source>Experimental Cell Research</source><volume>397</volume><elocation-id>112301</elocation-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2020.112301</pub-id><pub-id pub-id-type="pmid">32979364</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashi</surname><given-names>K</given-names></name><name><surname>Matsuzaki</surname><given-names>E</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Takahashi-Yanaga</surname><given-names>F</given-names></name><name><surname>Takano</surname><given-names>A</given-names></name><name><surname>Anan</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sphingosine-1-phosphate/S1PR2-mediated signaling triggers SMAD1/5/8 phosphorylation and thereby induces Runx2 expression in osteoblasts</article-title><source>Bone</source><volume>93</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2016.09.003</pub-id><pub-id pub-id-type="pmid">27612439</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Roth</surname><given-names>TM</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Verdin</surname><given-names>EM</given-names></name><name><surname>Hsiao</surname><given-names>EC</given-names></name><name><surname>Nissenson</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Sirtuin-3 promotes adipogenesis, osteoclastogenesis, and bone loss in aging male mice</article-title><source>Endocrinology</source><volume>158</volume><fpage>2741</fpage><lpage>2753</lpage><pub-id pub-id-type="doi">10.1210/en.2016-1739</pub-id><pub-id pub-id-type="pmid">28911171</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsin</surname><given-names>JP</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Loeb</surname><given-names>GB</given-names></name><name><surname>Leslie</surname><given-names>CS</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types</article-title><source>Nature Immunology</source><volume>19</volume><fpage>1137</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0208-x</pub-id><pub-id pub-id-type="pmid">30224821</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Wismeijer</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Hunziker</surname><given-names>EB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hyaluronic acid promotes the osteogenesis of BMP-2 in an absorbable collagen sponge</article-title><source>Polymers</source><volume>9</volume><elocation-id>339</elocation-id><pub-id pub-id-type="doi">10.3390/polym9080339</pub-id><pub-id pub-id-type="pmid">30971019</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaafar</surname><given-names>M</given-names></name><name><surname>Zubairi</surname><given-names>SI</given-names></name><name><surname>Yahaya</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Physico-mechanical properties of HA/TCP pellets and their three-dimensional biological evaluation in vitro</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1084</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/5584_2017_130</pub-id><pub-id pub-id-type="pmid">29299875</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagiya</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation</article-title><source>Journal of Periodontal Research</source><volume>48</volume><fpage>373</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1111/jre.12017</pub-id><pub-id pub-id-type="pmid">23078176</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kardani</surname><given-names>A</given-names></name><name><surname>Yaghoobi</surname><given-names>H</given-names></name><name><surname>Alibakhshi</surname><given-names>A</given-names></name><name><surname>Khatami</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inhibition of miR-155 in MCF-7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer</article-title><source>Journal of Cellular Physiology</source><volume>235</volume><fpage>6887</fpage><lpage>6895</lpage><pub-id pub-id-type="doi">10.1002/jcp.29584</pub-id><pub-id pub-id-type="pmid">32003016</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalife</surname><given-names>J</given-names></name><name><surname>Radomska</surname><given-names>HS</given-names></name><name><surname>Santhanam</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Neviani</surname><given-names>P</given-names></name><name><surname>Saultz</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y-Z</given-names></name><name><surname>Alachkar</surname><given-names>H</given-names></name><name><surname>Anghelina</surname><given-names>M</given-names></name><name><surname>Dorrance</surname><given-names>A</given-names></name><name><surname>Curfman</surname><given-names>J</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Medeiros</surname><given-names>BC</given-names></name><name><surname>Perrotti</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>LJ</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Pichiorri</surname><given-names>F</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name><name><surname>Garzon</surname><given-names>R</given-names></name><name><surname>Guzman</surname><given-names>ML</given-names></name><name><surname>Mendler</surname><given-names>JH</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia</article-title><source>Leukemia</source><volume>29</volume><fpage>1981</fpage><lpage>1992</lpage><pub-id pub-id-type="doi">10.1038/leu.2015.106</pub-id><pub-id pub-id-type="pmid">25971362</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitaura</surname><given-names>H</given-names></name><name><surname>Marahleh</surname><given-names>A</given-names></name><name><surname>Ohori</surname><given-names>F</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>WR</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Nara</surname><given-names>Y</given-names></name><name><surname>Pramusita</surname><given-names>A</given-names></name><name><surname>Kinjo</surname><given-names>R</given-names></name><name><surname>Mizoguchi</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Osteocyte-related cytokines regulate osteoclast formation and bone resorption</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21145169</pub-id><pub-id pub-id-type="pmid">32708317</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Vijayan</surname><given-names>M</given-names></name><name><surname>Bhatti</surname><given-names>JS</given-names></name><name><surname>Reddy</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Micrornas as peripheral biomarkers in aging and age-related diseases</article-title><source>Progress in Molecular Biology and Translational Science</source><volume>146</volume><fpage>47</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2016.12.013</pub-id><pub-id pub-id-type="pmid">28253991</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>WY-W</given-names></name><name><surname>Lin</surname><given-names>S-E</given-names></name><name><surname>Ni</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>X-R</given-names></name><name><surname>Lan</surname><given-names>H-Y</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Partial loss of Smad7 function impairs bone remodeling, osteogenesis and enhances osteoclastogenesis in mice</article-title><source>Bone</source><volume>67</volume><fpage>46</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2014.06.033</pub-id><pub-id pub-id-type="pmid">24998669</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>KC</given-names></name><name><surname>Lo</surname><given-names>SC</given-names></name><name><surname>Sung</surname><given-names>LY</given-names></name><name><surname>Liao</surname><given-names>YH</given-names></name><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Hu</surname><given-names>YC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Improved calvarial bone repair by hascs engineered with cre/loxp-based baculovirus conferring prolonged BMP-2 and mir-148b co-expression</article-title><source>Journal of Tissue Engineering and Regenerative Medicine</source><volume>11</volume><fpage>3068</fpage><lpage>3077</lpage><pub-id pub-id-type="doi">10.1002/term.2208</pub-id><pub-id pub-id-type="pmid">27687795</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>GS</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>MiR-155-5p regulates macrophage M1 polarization and apoptosis in the synovial fluid of patients with knee osteoarthritis</article-title><source>Experimental and Therapeutic Medicine</source><volume>21</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.3892/etm.2020.9500</pub-id><pub-id pub-id-type="pmid">33365068</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Saaoud</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Hodge</surname><given-names>J</given-names></name><name><surname>Hui</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Lessner</surname><given-names>SM</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>MiR155 modulates vascular calcification by regulating akt-foxo3a signalling and apoptosis in vascular smooth muscle cells</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>25</volume><fpage>535</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1111/jcmm.16107</pub-id><pub-id pub-id-type="pmid">33210462</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Weng</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Dai</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021c</year><article-title>BATF3 promotes malignant phenotype of colorectal cancer through the S1PR1/p-STAT3/mir-155-3p/WDR82 axis</article-title><source>Cancer Gene Therapy</source><volume>28</volume><fpage>400</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1038/s41417-020-00223-2</pub-id><pub-id pub-id-type="pmid">33057139</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Du</surname><given-names>T</given-names></name><name><surname>Xiao</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mir-155 enhances insulin sensitivity by coordinated regulation of multiple genes in mice</article-title><source>PLOS Genetics</source><volume>12</volume><elocation-id>e1006308</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006308</pub-id><pub-id pub-id-type="pmid">27711113</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Microrna-155 inhibits the osteogenic differentiation of mesenchymal stem cells induced by BMP9 via downregulation of BMP signaling pathway</article-title><source>International Journal of Molecular Medicine</source><volume>41</volume><fpage>3379</fpage><lpage>3393</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2018.3526</pub-id><pub-id pub-id-type="pmid">29512689</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>GB</given-names></name><name><surname>Kang</surname><given-names>YC</given-names></name><name><surname>Brand</surname><given-names>C</given-names></name><name><surname>Ebeling</surname><given-names>PR</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance</article-title><source>Journal of Clinical Oncology</source><volume>27</volume><fpage>3605</fpage><lpage>3610</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.20.2549</pub-id><pub-id pub-id-type="pmid">19546403</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moussa</surname><given-names>FM</given-names></name><name><surname>Cook</surname><given-names>BP</given-names></name><name><surname>Sondag</surname><given-names>GR</given-names></name><name><surname>DeSanto</surname><given-names>M</given-names></name><name><surname>Obri</surname><given-names>MS</given-names></name><name><surname>McDermott</surname><given-names>SE</given-names></name><name><surname>Safadi</surname><given-names>FF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The role of mir-150 regulates bone cell differentiation and function</article-title><source>Bone</source><volume>145</volume><elocation-id>115470</elocation-id><pub-id pub-id-type="doi">10.1016/j.bone.2020.115470</pub-id><pub-id pub-id-type="pmid">32526406</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okoye</surname><given-names>IS</given-names></name><name><surname>Czieso</surname><given-names>S</given-names></name><name><surname>Ktistaki</surname><given-names>E</given-names></name><name><surname>Roderick</surname><given-names>K</given-names></name><name><surname>Coomes</surname><given-names>SM</given-names></name><name><surname>Pelly</surname><given-names>VS</given-names></name><name><surname>Kannan</surname><given-names>Y</given-names></name><name><surname>Perez-Lloret</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>JL</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name><name><surname>Langhorne</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Transcriptomics identified a critical role for th2 cell-intrinsic mir-155 in mediating allergy and antihelminth immunity</article-title><source>PNAS</source><volume>111</volume><fpage>E3081</fpage><lpage>E3090</lpage><pub-id pub-id-type="doi">10.1073/pnas.1406322111</pub-id><pub-id pub-id-type="pmid">25024218</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Ling</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Metal-Organic framework nanoparticles for ameliorating breast cancer-associated osteolysis</article-title><source>Nano Letters</source><volume>20</volume><fpage>829</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b02916</pub-id><pub-id pub-id-type="pmid">31916446</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasculli</surname><given-names>B</given-names></name><name><surname>Barbano</surname><given-names>R</given-names></name><name><surname>Fontana</surname><given-names>A</given-names></name><name><surname>Biagini</surname><given-names>T</given-names></name><name><surname>Di Viesti</surname><given-names>MP</given-names></name><name><surname>Rendina</surname><given-names>M</given-names></name><name><surname>Valori</surname><given-names>VM</given-names></name><name><surname>Morritti</surname><given-names>M</given-names></name><name><surname>Bravaccini</surname><given-names>S</given-names></name><name><surname>Ravaioli</surname><given-names>S</given-names></name><name><surname>Maiello</surname><given-names>E</given-names></name><name><surname>Graziano</surname><given-names>P</given-names></name><name><surname>Murgo</surname><given-names>R</given-names></name><name><surname>Copetti</surname><given-names>M</given-names></name><name><surname>Mazza</surname><given-names>T</given-names></name><name><surname>Fazio</surname><given-names>VM</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Parrella</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hsa-mir-155-5p up-regulation in breast cancer and its relevance for treatment with poly [ ADP-ribose ] polymerase 1 (PARP-1) inhibitors</article-title><source>Frontiers in Oncology</source><volume>10</volume><elocation-id>1415</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.01415</pub-id><pub-id pub-id-type="pmid">32903519</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mir-155 inhibition alleviates suppression of osteoblastic differentiation by high glucose and free fatty acids in human bone marrow stromal cells by upregulating SIRT1</article-title><source>Pflugers Archiv</source><volume>472</volume><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1007/s00424-020-02372-7</pub-id><pub-id pub-id-type="pmid">32248286</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Readhead</surname><given-names>B</given-names></name><name><surname>Haure-Mirande</surname><given-names>J-V</given-names></name><name><surname>Mastroeni</surname><given-names>D</given-names></name><name><surname>Audrain</surname><given-names>M</given-names></name><name><surname>Fanutza</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Blitzer</surname><given-names>RD</given-names></name><name><surname>Gandy</surname><given-names>S</given-names></name><name><surname>Dudley</surname><given-names>JT</given-names></name><name><surname>Ehrlich</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MiR155 regulation of behavior, neuropathology, and cortical transcriptomics in Alzheimer’s disease</article-title><source>Acta Neuropathologica</source><volume>140</volume><fpage>295</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1007/s00401-020-02185-z</pub-id><pub-id pub-id-type="pmid">32666270</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>R</given-names></name><name><surname>Rodríguez</surname><given-names>JA</given-names></name><name><surname>Orbe</surname><given-names>J</given-names></name><name><surname>Arnau</surname><given-names>MR</given-names></name><name><surname>Évora</surname><given-names>C</given-names></name><name><surname>Delgado</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Combined sustained release of BMP2 and MMP10 accelerates bone formation and mineralization of calvaria critical size defect in mice</article-title><source>Drug Delivery</source><volume>25</volume><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1080/10717544.2018.1446473</pub-id><pub-id pub-id-type="pmid">29516759</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roodman</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Biology of osteoclast activation in cancer</article-title><source>Journal of Clinical Oncology</source><volume>19</volume><fpage>3562</fpage><lpage>3571</lpage><pub-id pub-id-type="doi">10.1200/JCO.2001.19.15.3562</pub-id><pub-id pub-id-type="pmid">11481364</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>C</given-names></name><name><surname>Iwasaki</surname><given-names>T</given-names></name><name><surname>Kitano</surname><given-names>S</given-names></name><name><surname>Tsunemi</surname><given-names>S</given-names></name><name><surname>Sano</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation</article-title><source>Biochemical and Biophysical Research Communications</source><volume>423</volume><fpage>200</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.05.130</pub-id><pub-id pub-id-type="pmid">22659743</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Schwinge</surname><given-names>D</given-names></name><name><surname>Rolvien</surname><given-names>T</given-names></name><name><surname>Jeschke</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Neven</surname><given-names>M</given-names></name><name><surname>Butscheidt</surname><given-names>S</given-names></name><name><surname>Kriz</surname><given-names>M</given-names></name><name><surname>Kunzmann</surname><given-names>L</given-names></name><name><surname>Mussawy</surname><given-names>H</given-names></name><name><surname>Hubert</surname><given-names>J</given-names></name><name><surname>Hawellek</surname><given-names>T</given-names></name><name><surname>Rüther</surname><given-names>W</given-names></name><name><surname>Oheim</surname><given-names>R</given-names></name><name><surname>Barvencik</surname><given-names>F</given-names></name><name><surname>Lohse</surname><given-names>AW</given-names></name><name><surname>Schramm</surname><given-names>C</given-names></name><name><surname>Schinke</surname><given-names>T</given-names></name><name><surname>Amling</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis</article-title><source>Journal of Hepatology</source><volume>70</volume><fpage>941</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.12.035</pub-id><pub-id pub-id-type="pmid">30641095</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>CC</given-names></name><name><surname>Yang</surname><given-names>FM</given-names></name><name><surname>Qin</surname><given-names>ZQ</given-names></name><name><surname>Jing</surname><given-names>XM</given-names></name><name><surname>Shu</surname><given-names>YQ</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis</article-title><source>BMC Cancer</source><volume>19</volume><elocation-id>1103</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-019-6297-6</pub-id><pub-id pub-id-type="pmid">31727002</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soleimani</surname><given-names>M</given-names></name><name><surname>Nadri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow</article-title><source>Nature Protocols</source><volume>4</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.221</pub-id><pub-id pub-id-type="pmid">19131962</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Azevedo</surname><given-names>HS</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Intracellular codelivery of anti-inflammatory drug and anti-MIR 155 to treat inflammatory disease</article-title><source>Acta Pharmaceutica Sinica. B</source><volume>10</volume><fpage>1521</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2020.06.005</pub-id><pub-id pub-id-type="pmid">32963947</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>JW</given-names></name><name><surname>Bian</surname><given-names>SS</given-names></name><name><surname>Kong</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>YG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Icariin triggers osteogenic differentiation of bone marrow stem cells by up-regulating mir-335-5p</article-title><source>Experimental Cell Research</source><volume>414</volume><elocation-id>113085</elocation-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2022.113085</pub-id><pub-id pub-id-type="pmid">35292240</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomé</surname><given-names>M</given-names></name><name><surname>López-Romero</surname><given-names>P</given-names></name><name><surname>Albo</surname><given-names>C</given-names></name><name><surname>Sepúlveda</surname><given-names>JC</given-names></name><name><surname>Fernández-Gutiérrez</surname><given-names>B</given-names></name><name><surname>Dopazo</surname><given-names>A</given-names></name><name><surname>Bernad</surname><given-names>A</given-names></name><name><surname>González</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mir-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells</article-title><source>Cell Death &amp; Differentiation</source><volume>18</volume><fpage>985</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1038/cdd.2010.167</pub-id><pub-id pub-id-type="pmid">21164520</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A regulatory loop containing mir-26a, GSK3β and C/EBPα regulates the osteogenesis of human adipose-derived mesenchymal stem cells</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>15280</elocation-id><pub-id pub-id-type="doi">10.1038/srep15280</pub-id><pub-id pub-id-type="pmid">26469406</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>ZJ</given-names></name><name><surname>Jia</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>YL</given-names></name><name><surname>Xue</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of p53/mir-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease</article-title><source>Journal of Translational Medicine</source><volume>16</volume><elocation-id>146</elocation-id><pub-id pub-id-type="doi">10.1186/s12967-018-1486-7</pub-id><pub-id pub-id-type="pmid">29848325</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Roles for mirnas in osteogenic differentiation of bone marrow mesenchymal stem cells</article-title><source>Stem Cell Research &amp; Therapy</source><volume>10</volume><elocation-id>197</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-019-1309-7</pub-id><pub-id pub-id-type="pmid">31253175</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liang</surname><given-names>R</given-names></name><name><surname>Tandon</surname><given-names>N</given-names></name><name><surname>Matthews</surname><given-names>ER</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Soibam</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>H19X-encoded mir-424 (322) /-503 cluster: emerging roles in cell differentiation, proliferation, plasticity and metabolism</article-title><source>Cellular and Molecular Life Sciences</source><volume>76</volume><fpage>903</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1007/s00018-018-2971-0</pub-id><pub-id pub-id-type="pmid">30474694</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Gong</surname><given-names>F</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Lv</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019c</year><article-title>MicroRNA-30c abrogation protects against spinal cord ischemia reperfusion injury through modulating SIRT1</article-title><source>European Journal of Pharmacology</source><volume>851</volume><fpage>80</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2019.02.027</pub-id><pub-id pub-id-type="pmid">30776367</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Lan</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>N</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Jaspers</surname><given-names>RT</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Pathak</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Notoginsenoside R1 promotes migration, adhesin, spreading, and osteogenic differentiation of human adipose tissue-derived mesenchymal stromal cells</article-title><source>Molecules</source><volume>27</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27113403</pub-id><pub-id pub-id-type="pmid">35684342</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witten</surname><given-names>L</given-names></name><name><surname>Slack</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mir-155 as a novel clinical target for hematological malignancies</article-title><source>Carcinogenesis</source><volume>41</volume><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgz183</pub-id><pub-id pub-id-type="pmid">31711135</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woeller</surname><given-names>CF</given-names></name><name><surname>Roztocil</surname><given-names>E</given-names></name><name><surname>Hammond</surname><given-names>C</given-names></name><name><surname>Feldon</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tshr signaling stimulates proliferation through PI3K/Akt and induction of miR-146a and miR-155 in thyroid eye disease orbital fibroblasts</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>60</volume><fpage>4336</fpage><lpage>4345</lpage><pub-id pub-id-type="doi">10.1167/iovs.19-27865</pub-id><pub-id pub-id-type="pmid">31622470</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression</article-title><source>Molecular Cancer</source><volume>17</volume><elocation-id>155</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-018-0899-5</pub-id><pub-id pub-id-type="pmid">30359265</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Expression of miR-155 and miR-146a in the saliva of patients with periodontitis and its clinical value</article-title><source>American Journal of Translational Research</source><volume>13</volume><fpage>6670</fpage><lpage>6677</lpage><pub-id pub-id-type="pmid">34306411</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The role of mir-135-modified adipose-derived mesenchymal stem cells in bone regeneration</article-title><source>Biomaterials</source><volume>75</volume><fpage>279</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.10.042</pub-id><pub-id pub-id-type="pmid">26513420</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Zhuang</surname><given-names>A</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effects of mir-146a on the osteogenesis of adipose-derived mesenchymal stem cells and bone regeneration</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>42840</elocation-id><pub-id pub-id-type="doi">10.1038/srep42840</pub-id><pub-id pub-id-type="pmid">28205638</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Dang</surname><given-names>J</given-names></name><name><surname>Bian</surname><given-names>X</given-names></name><name><surname>Shan</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mir-155 deficiency ameliorates autoimmune inflammation of systemic lupus erythematosus by targeting S1PR1 in faslpr/lpr mice</article-title><source>Journal of Immunology</source><volume>194</volume><fpage>5437</fpage><lpage>5445</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1403028</pub-id><pub-id pub-id-type="pmid">25911753</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Pu</surname><given-names>H</given-names></name><name><surname>Gui</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mir-155 accelerates the growth of human liver cancer cells by activating CDK2 via targeting H3F3A</article-title><source>Molecular Therapy Oncolytics</source><volume>17</volume><fpage>471</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.omto.2020.05.002</pub-id><pub-id pub-id-type="pmid">32490171</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Bhattarai</surname><given-names>U</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>F-S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cyclic peptidomimetics as inhibitor for miR-155 biogenesis</article-title><source>Molecular Pharmaceutics</source><volume>16</volume><fpage>914</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b01247</pub-id><pub-id pub-id-type="pmid">30601666</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>HL</given-names></name><name><surname>Zeng</surname><given-names>DW</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>JJ</given-names></name><name><surname>Xi</surname><given-names>QY</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ghrh expression plasmid improves osteoporosis and skin damage in aged mice</article-title><source>Growth Hormone &amp; IGF Research</source><volume>60–61</volume><elocation-id>101429</elocation-id><pub-id pub-id-type="doi">10.1016/j.ghir.2021.101429</pub-id><pub-id pub-id-type="pmid">34507253</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>CH</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Balian</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>XJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mir-221 attenuates the osteogenic differentiation of human annulus fibrosus cells</article-title><source>The Spine Journal</source><volume>16</volume><fpage>896</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.spinee.2016.03.026</pub-id><pub-id pub-id-type="pmid">26997108</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Cui</surname><given-names>YC</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>XK</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A comparative study of the characterization of miR-155 in knockout mice</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0173487</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0173487</pub-id><pub-id pub-id-type="pmid">28278287</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sdf-1 mediates mesenchymal stem cell recruitment and migration via the SDF-1/CXCR4 axis in bone defect</article-title><source>Journal of Bone and Mineral Metabolism</source><volume>39</volume><fpage>126</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1007/s00774-020-01122-0</pub-id><pub-id pub-id-type="pmid">33079278</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Downregulated adaptor protein p66 (Shc) mitigates autophagy process by low nutrient and enhances apoptotic resistance in human lung adenocarcinoma A549 cells</article-title><source>The FEBS Journal</source><volume>280</volume><fpage>4522</fpage><lpage>4530</lpage><pub-id pub-id-type="doi">10.1111/febs.12416</pub-id><pub-id pub-id-type="pmid">23815759</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>Z-K</given-names></name><name><surname>Jiang</surname><given-names>X-X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X-Y</given-names></name><name><surname>Yao</surname><given-names>H-Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone</article-title><source>Nature Protocols</source><volume>5</volume><fpage>550</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.238</pub-id><pub-id pub-id-type="pmid">20203670</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77742.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Trivedi</surname><given-names>Ritu</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021wm7p51</institution-id><institution>CSIR-Central Drug Research Institute</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.02.18.480982" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.18.480982"/></front-stub><body><p>The authors have shown the important role of miR155 in promoting bone regeneration and higher bone mass. Their fundamental work shows compelling evidence that miR155 is overexpressed in inflammatory diseases therefore, the use of anti-miR155 could produce anti-inflammatory effects. This shows the importance of miR155 inhibitors as therapeutics to promote bone regeneration in inflammatory conditions.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77742.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Trivedi</surname><given-names>Ritu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021wm7p51</institution-id><institution>CSIR-Central Drug Research Institute</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Karvande</surname><given-names>Anirudh</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01z7r7q48</institution-id><institution>The Childrens Hospital of Philadelphia</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.18.480982">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.02.18.480982v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;MicroRNA-155 regulates osteogenesis and bone mass phenotype via targeting S1PR1 gene&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Anirudh Karvande (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>In this study entitled &quot; MicroRNA-155 regulates osteogenesis and bone mass phenotype via targeting S1PR1 gene&quot; the authors have shown that miR155 showed a catabolic effect on osteogenesis and bone mass phenotype via interaction with the Sphingosine 1-phosphate receptor-1 (S1PR1) gene. It is also suggested that inhibition of miR155 is a potential strategy for bone regeneration and bone defect healing. It is an important study as cancer/cancer metastasis-induced bone loss-mediated fracture is a serious clinical problem. The authors have shown that miR155 as a potential strategy for bone regeneration and bone defect healing. However, the authors should address the concerns of the reviewers before the manuscript may be accepted for publication.</p><p>1. As cancer/cancer metastasis-induced bone loss is not gender specific it is important to know if the similar effects are observed in female mice? Authors did experiments in 8 week old male mice. Does this high bone mass phenotype in miR-155 KO or miR-155 Tg mice change over the period of time as mice age? It would be interesting in bone field if these mice are resistant/prone to age related bone loss or inflamaging.</p><p>2. Bone microarchitecture at the histological level need to be analyzed so as to compare the trabecular integrity in both miR155-Tg and miR155-KO mice. The demonstration of S1PR1 expression in a tissue-specific manner in both the groups through immunohistochemistry would validate the hypothesis in an effective way.</p><p>3. The study aims at the osteogenic efficacy of miR155, although experiments involving modulation in the resorption levels will support the results convincingly. TRAP staining for the detection of activated osteoclasts at the cellular level will further validate the hypothesis. Authors should mention and explain these effects in the results and discussion.</p><p>4. In figure 3, the authors fail to describe the differences observed among the micro CT parameters of the wild-type group in both studies. Clarification is required in this regard.</p><p>5. In figure 4A, authors are advised to represent a good 3D image of calvarial defect where at least the findings are properly depicted. What are the effects on Dynamic histomorphometry in miR-155 TG and miR-155 KO mice? Calcein/Alizarin Red injections followed by histomorphentry will be important to study Bone formation and mineral apposition rates.</p><p>6. The findings suggest an overall increase in the bone mass in the absence of miR155, but the experiments are restricted to the trabecular region, authors do not mention any variations observed in the cortical region. Data supporting the changes in cortical region would make the manuscript more acceptable.</p><p>7. Osteogenesis and osteoclastogenesis both result in altered serum and urinary marker production. Analysis of differentially regulated markers is suggested. What are the effects on serum levels of bone formation and resorption markers in miR-155 TG and miR-155 KO mice? PINP or Osteoclacin and CTX-1 eliza will be important to study how these mice lose or gain bone.</p><p>8. As mentioned by the authors in the abstract that miR155-KO mice show robust bone regeneration in the ectopic and orthotopic models. The authors have not evaluated the pleiotropic effects posed by knocking down mir-155 such as vascular calcification or mineralization. Are there any reports of vital organs being affected in KO mice?</p><p>9. Estimation of Expression of RANK and Cathepsin K is also suggested to understand if KO of miRNA- 155 is affecting the osteoclastogenesis process</p><p>10. What are the expression levels of miR-155 in bone tissue from miR-155 Tg and miR-155 KO mice? It is important to show miR-155 levels are reduced or knocked down in miR-155 KO bones and increased in miR-155 Tg bones. Authors should mention and explain these effects in the results and discussion.</p><p>11. Authors observed no change or possible reduction in Runx2 levels in miR-155 KO BMSCs. However, they observed an increase in Runx2 levels in BMSCs treated with miR-155 sponge. The authors should mention and explain why they did not observe increased Runx2 levels in miR-155 KO BMSCs, in the result and discussion.</p><p>12. Authors showed binding site of miR-155-5p in the 3'UTR of S1PR1 gene but did not mention whether it is conserved among different species like mouse, human or rat etc. Authors should comment on these points in the result and discussion.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. In the present manuscript the bone microarchitecture at the histological level needs to be analyzed so as to compare the trabecular integrity in both miR155-Tg and miR155-KO mice. The demonstration of S1PR1 expression in a tissue-specific manner in both the groups through immunohistochemistry would validate the hypothesis in an effective way.</p><p>2. The study aims at the osteogenic efficacy of miR155, although experiments involving modulation in the resorption levels will support the results convincingly. TRAP staining for the detection of activated osteoclasts at the cellular level will further validate the hypothesis.</p><p>3. The manuscript could do with careful editing and typographical correction.</p><p>4. Authors are required to provide references for each of the methodologies used in the study.</p><p>5. In figure 3, the authors fail to describe the differences observed among the micro CT parameters of the wild-type group in both studies. Please clarify.</p><p>6. In figure 4A, authors are advised to represent a good 3D image of calvarial defect where at least the findings can be shown properly.</p><p>7. The findings suggest an overall increase in the bone mass in the absence of miR155, but the experiments are restricted to the trabecular region, authors do not mention any variations observed in the cortical region. Data supporting the changes in cortical region would make the manuscript more acceptable.</p><p>8. Osteogenesis and osteoclastogenesis both result in altered serum and urinary marker production. A brief analysis of differentially regulated markers is suggested.</p><p>9. As mentioned by the authors in the abstract that miR155-KO mice show robust bone regeneration in the ectopic and orthotopic models. The authors have not evaluated the pleiotropic effects posed by knocking down mir-155 such as vascular calcification or mineralization. Are there any reports of vital organs being affected in KO mice?</p><p>10. Line 117-119 should be reframed to properly explain the fold increase in micro-CT parameters in KO mice compared to control.</p><p>11. Densitometry of western blots should be incorporated by the authors.</p><p>12. In figure 7F the loading control i.e., GAPDH is not equal in both the groups. Quantification should be provided.</p><p>13. Estimation of Expression of RANK and Cathepsin K is also suggested to understand if KO of miRNA- 155 is affecting the osteoclastogenesis process</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Result 6, Page 7, line 195-196, miR-155 was knockdown…….in oetogenic differentiation. Please revise the sentence.</p><p>2.Result 7, Page 8, line 208-207, miR-155 robustly enhanced…….in BMSCs. It should be miR-155 sponge instead of miR-155. Please revise the sentence.</p><p>3. Authors should revise the figures. Phenotypic results which include microCT data should be in one figure rather than two small different figures. For e.g Figure 1 and 2 should be combined.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The author could characterize MSCs by flowcytometry post-silencing of miR155, instead of only focusing on how they proliferate and differentiate.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77742.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>In this study entitled &quot; MicroRNA-155 regulates osteogenesis and bone mass phenotype via targeting S1PR1 gene&quot; the authors have shown that miR155 showed a catabolic effect on osteogenesis and bone mass phenotype via interaction with the Sphingosine 1-phosphate receptor-1 (S1PR1) gene. It is also suggested that inhibition of miR155 is a potential strategy for bone regeneration and bone defect healing. It is an important study as cancer/cancer metastasis-induced bone loss-mediated fracture is a serious clinical problem. The authors have shown that miR155 as a potential strategy for bone regeneration and bone defect healing. However, the authors should address the concerns of the reviewers before the manuscript may be accepted for publication.</p><p>1. As cancer/cancer metastasis-induced bone loss is not gender specific it is important to know if the similar effects are observed in female mice? Authors did experiments in 8 week old male mice. Does this high bone mass phenotype in miR-155 KO or miR-155 Tg mice change over the period of time as mice age? It would be interesting in bone field if these mice are resistant/prone to age related bone loss or inflamaging.</p></disp-quote><p>We used a total of 8 mice, of which 4 were male and 4 were female mice. At the 8-week-old age, bone parameters in male and female mice were almost similar, therefore we combined the total 8 mice (male and female) data (Figure 1 and 2). Due to a too-long period required to generate aged mice, we were unable to analyze bone parameters in aged mice. However, we have now performed additional experiments to test the role of <italic>Mir155</italic> on inflammation-related bone loss. These results are now provided in Figure 3. We found that <italic>Mir155</italic>-KO prevents LPS-induced bone loss. The levels of cortical bone and trabecular bone were significantly increased in LPS treated <italic>Mir155</italic>-KO mice compared to wild-type.</p><disp-quote content-type="editor-comment"><p>2. Bone microarchitecture at the histological level need to be analyzed so as to compare the trabecular integrity in both miR155-Tg and miR155-KO mice. The demonstration of S1PR1 expression in a tissue-specific manner in both the groups through immunohistochemistry would validate the hypothesis in an effective way.</p></disp-quote><p>The bone microarchitecture of <italic>Mir155</italic>-Tg and <italic>Mir155</italic>-KO mice at the histological level have now been analyzed and are shown by H&amp;E staining in Figure 1B and Figure 2B, respectively. We performed the immunohistochemistry for S1PR1 using three antibodies from different companies available in China. Unfortunately, these antibodies did not work.</p><disp-quote content-type="editor-comment"><p>3. The study aims at the osteogenic efficacy of miR155, although experiments involving modulation in the resorption levels will support the results convincingly. TRAP staining for the detection of activated osteoclasts at the cellular level will further validate the hypothesis. Authors should mention and explain these effects in the results and discussion.</p></disp-quote><p>We agree that TRAP staining provides an more detailed insight on the effects of <italic>Mir155</italic> on bone resorption. To test the effect of <italic>Mir155</italic> on osteoclast formation, we isolated bone marrow cells from <italic>Mir155</italic>-KO mice and WT mice and induced the cells with M-CSF (50 ng/mL) for 4 days. After that RANKL (50 ng/mL) was added for osteoclastogenic differentiation for 7 days. TRAP staining and osteoclast counting were performed. Information and results have been added to the Materials and methods, results, and Discussion section. The figures of thee experiments are presented in Figure 9. The experiments show that <italic>Mir155</italic>-KO inhibits osteoclastogenesis.</p><disp-quote content-type="editor-comment"><p>4. In figure 3, the authors fail to describe the differences observed among the micro CT parameters of the wild-type group in both studies. Clarification is required in this regard.</p></disp-quote><p>The <italic>Mir155</italic> KO mice were C57BL/6J background, and <italic>Mir155</italic>-Tg mice were FVB background. The differences in Micro CT parameters of the wild-type groups may have resulted from a different background of wild-type mice.</p><disp-quote content-type="editor-comment"><p>5. In figure 4A, authors are advised to represent a good 3D image of calvarial defect where at least the findings are properly depicted. What are the effects on Dynamic histomorphometry in miR-155 TG and miR-155 KO mice? Calcein/Alizarin Red injections followed by histomorphentry will be important to study Bone formation and mineral apposition rates.</p></disp-quote><p>We used the calvarial defect model without adding osteoinductive factors in <italic>Mir155</italic>-KO mice and WT mice. The recovery of bone defect was not very good after 1 month, which may have influenced the 3D image presentation. We have now put these results in Supplementary data. We performed a new experiment, in which BMP2 (180 ng) was applied to the collagen film and grafted into the defect of <italic>Mir155</italic>-KO mice and WT mice. After one month, the samples were collected and analyzed with microCT. The results of microCT and dynamic histomorphometry of this new experiment are shown in Figure 5. Calcein/Alizarin red staining is a good way to detect the dynamic bone formation, however, due to the lack of a hard tissue sectioning instrument in our facility, we were unable to visualize Calcein/Alizarin Red labeling.</p><disp-quote content-type="editor-comment"><p>6. The findings suggest an overall increase in the bone mass in the absence of miR155, but the experiments are restricted to the trabecular region, authors do not mention any variations observed in the cortical region. Data supporting the changes in cortical region would make the manuscript more acceptable.</p></disp-quote><p>We now have also analyzed the cortical region. The results of cortical region analysis are shown in Figure 1C, 1D, 2C, and 2D. These data show that reduced cortical bone level and bone volume/total volume (BV/TV) in <italic>Mir155-Tg</italic> mice. And a higher cortical bone level and BV/TV was shown in <italic>Mir155</italic>-KO mice.</p><disp-quote content-type="editor-comment"><p>7. Osteogenesis and osteoclastogenesis both result in altered serum and urinary marker production. Analysis of differentially regulated markers is suggested. What are the effects on serum levels of bone formation and resorption markers in miR-155 TG and miR-155 KO mice? PINP or Osteoclacin and CTX-1 eliza will be important to study how these mice lose or gain bone.</p></disp-quote><p>As suggested by the reviewer, we collected the serums from <italic>Mir155-</italic>KO mice and WT mice. The PINP and CTX-1 were detected by ELISA. As shown in Figure 9D, the level of PINP was significantly increased while CTX-1 was reduced in <italic>Mir155</italic>-KO mice compared to WT mice, which is consistent with the bone phenotype in vivo. Due to a lack of enough <italic>Mir155</italic>-Tg mice, we were unable to analyze PINP and CTX-1 levels in these mice's serum.</p><disp-quote content-type="editor-comment"><p>8. As mentioned by the authors in the abstract that miR155-KO mice show robust bone regeneration in the ectopic and orthotopic models. The authors have not evaluated the pleiotropic effects posed by knocking down mir-155 such as vascular calcification or mineralization. Are there any reports of vital organs being affected in KO mice?</p></disp-quote><p>Reports from the literature have shown the inhibition of vascular calcification in <italic>Mir155</italic>-KO mice. Therefore, we did not perform this experiment. For better clarification, we added the following text in the Discussion section (page 13, line 366-376): “Clinical application of osteogenic factors in vivo always poses the risk of vascular calcification. miR155-5p overexpression has been reported to aggravate vascular calcification <sup>(55)</sup>. Importantly, <italic>Mir155</italic>-KO mice also show resistance against vitamin D3-induced vascular calcification <sup>(56)</sup>. Moreover, <italic>Mir155</italic> deletion inhibits the migration and apoptosis of vascular smooth muscle cells as well as vascular calcification <sup>(56)</sup>. Furthermore, Zhang et al. showed normal histology of vital organs including the heart, lung, liver, and spleen in <italic>Mir155</italic>-KO mice <sup>(57)</sup>. These reports from the literature indicate that <italic>Mir155</italic>-KO knockout does not pose the risk of vascular calcification. However, the effect of <italic>Mir155</italic> inhibitors or anti-<italic>Mir155</italic> on vascular calcification should be thoroughly investigated before applying these agents for bone regeneration applications.”</p><disp-quote content-type="editor-comment"><p>9. Estimation of Expression of RANK and Cathepsin K is also suggested to understand if KO of miRNA- 155 is affecting the osteoclastogenesis process</p></disp-quote><p>The expression levels of <italic>Rank</italic> and <italic>Ctsk</italic> were significantly downregulated in <italic>Mir155</italic>-KO BMMs’ osteoclastogenic process. The results are shown in Figure 9C.</p><disp-quote content-type="editor-comment"><p>10. What are the expression levels of miR-155 in bone tissue from miR-155 Tg and miR-155 KO mice? It is important to show miR-155 levels are reduced or knocked down in miR-155 KO bones and increased in miR-155 Tg bones. Authors should mention and explain these effects in the results and discussion.</p></disp-quote><p>The <italic>Mir155</italic> levels were downregulated 0.079 fold in the <italic>Mir155</italic>-KO mice while upregulated 8.57 fold in the miR155-Tg mice bone tissues by RT-qPCR. The results are shown in Figure 1A and Figure 2A. We added the relevant information in the results and Discussion sections.</p><disp-quote content-type="editor-comment"><p>11. Authors observed no change or possible reduction in Runx2 levels in miR-155 KO BMSCs. However, they observed an increase in Runx2 levels in BMSCs treated with miR-155 sponge. The authors should mention and explain why they did not observe increased Runx2 levels in miR-155 KO BMSCs, in the result and discussion.</p></disp-quote><p>We had mentioned this effect in the result section of the original manuscript. We now have added the following text in the Discussion section (page 11, line 295-303): “Whole body knockout of <italic>Mir155</italic> also knock outs the <italic>Mir155</italic> in the other cell types present in bone microenvironment for example monocytes and macrophages. The <italic>Mir155</italic>-KO BMSCs might have certain effects of surrounding <italic>Mir155</italic>-KO other cell types on S1PR1 expression, while the <italic>Mir155</italic> sponged BMSCs from wild-type mice sorted with FACAS may be free from such effects. This could be the possible explanation for the lack of change in RUNX2 expression in <italic>Mir155</italic>-KO BMSCs, but rather an upregulation of RUNX2 expression in <italic>Mir155</italic> sponged BMSCs from wildtype mice observed in this study. However, further studies are required to support this logic.”</p></body></sub-article></article>